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2Abstract:
Systemic inflammation enhances the risk and progression of Alzheimer’s disease (AD).
Lipopolysaccharide (LPS), a potent pro-inflammatory endotoxin produced by the gut, is
found in excess levels in AD where it associates with neurological hallmarks of pathology.
Sex differences in susceptibility to inflammation and AD progression have been reported,
but how this impacts on LPS responses remains under investigated. We previously
reported in an APP/PS1 model of AD that systemic LPS administration rapidly altered
hippocampal metabolism in males. Here, we used untargeted metabolomics to
comprehensively identify hippocampal metabolic processes occurring at onset of systemic
inflammation with LPS (100µg/kg, i.v.) in APP/PS1 mice, at an early pathological stage,
and investigated the sexual dimorphism in this response. Four hours after LPS
administration, pathways regulating energy metabolism, immune and oxidative stress
responses were simultaneously recruited in the hippocampi of 4.5-month-old mice with a
more protective response in females despite their pro-inflammatory and pro-oxidant
metabolic signature in the absence of immune stimulation. LPS induced comparable
behavioural sickness responses in male and female wild-type and APP/PS1 mice and
comparable activation of both the serotonin and nicotinamide pathways of tryptophan
metabolism in their hippocampi. Elevations in N-methyl-2-pyridone-5-carboxamide, a
major toxic metabolite of nicotinamide, correlated with behavioural sickness regardless of
sex, as well as with the LPS-induced hypothermia seen in males. Males also exhibited a
pro-inflammatory-like downregulation of pyruvate metabolism, exacerbated in APP/PS1
males, and methionine metabolism whereas females showed a greater cytokine response
and anti-inflammatory-like downregulation of hippocampal methylglyoxal and methionine
metabolism. Metabolic changes were not associated with morphological markers of
immune cell activation suggesting that they constitute an early event in the development
of LPS-induced neuroinflammation and AD exacerbation. These data suggest that the
female hippocampus is more tolerant to acute systemic inflammation.
Keywords: Inflammation, Lipopolysaccharide, Alzheimer’s disease, APP/PS1 mouse
model, sex differences, hippocampus, microglia, metabolomics, serotonin, methionine.
31. Introduction
Alzheimer’s disease (AD), the most common senile dementia, is characterised by a
progressive cognitive decline accompanied by the accumulation of aggregated amyloid
beta (Aβ) plaques, neurofibrillary tangles made of hyperphosphorylated tau protein, 
severe brain atrophy and neuroinflammation. The causes of AD are far from being
understood, but systemic infection and inflammation have emerged as key modulators of
its risk and progression. A number of genes conferring susceptibility to inflammatory
conditions have indeed been found to be associated with a predisposition to AD (Karch
and Goate, 2015; Malik et al., 2015; Yokoyama et al., 2016), whereas circulating levels
of acute phase proteins or pro-inflammatory cytokines were found to be elevated in non-
demented subjects presenting with a higher risk of developing late-onset AD (Eikelenboom
et al., 2012; Koyama et al., 2013), and in patients in the prodromal, mild cognitive
impairment (MCI) phase of AD (Bettcher and Kramer, 2014; King et al., 2018; Trollor et
al., 2010). Infection-induced systemic inflammation has been proposed as a mechanistic
driver of AD pathogenesis (Ashraf et al., 2019; Giridharan et al., 2019), and the presence
of acute inflammatory events, such as respiratory infections or delirium have also been
associated with exacerbations of clinical presentation and precipitous cognitive decline in
AD patients (Holmer et al., 2018; Holmes et al., 2009; Ide et al., 2016). Altogether, this
suggests that AD patients and people at risk of developing the disease are more
susceptible to inflammatory conditions, and that such vulnerability contributes to the
development of clinical features of AD. The incidence and prevalence of AD are generally
higher in women, and although this may be due to their longer life expectancy, they
exhibit faster cognitive decline and brain atrophy than men (Ferretti et al., 2018;
Podcasy and Epperson, 2016) and are also thought to produce higher inflammatory
responses and be more susceptible to inflammatory conditions (Klein and Flanagan, 2016;
Roved et al., 2017). Some sex differences in the association between specific pro-
inflammatory mediators and clinical outcomes have been noted (Trollor et al., 2010), but
this has not been investigated in detail.
Systemic inflammation is thought to be the mechanism whereby acute,
accumulative or chronic infections can trigger AD pathogenesis (Ashraf et al., 2019;
Giridharan et al., 2019). In preclinical mouse models, lipopolysaccharide (LPS), mimicking
gram-negative bacterial infection, and other acute systemic inflammatory stimuli have
been found to exacerbate cognitive dysfunction, Aβ plaque load and tau phosphorylation 
(Barron et al., 2017; Cunningham and Hennessy, 2015; Nazem et al., 2015). While the
use of LPS to model systemic inflammation has been debated, in part because of the high
doses used which are more relevant to sepsis than to the chronic low grade inflammation
associated with ageing, MCI and AD (Barron et al., 2017; Cunningham and Hennessy,
42015; Varatharaj and Galea, 2017), a comparison of three models yielded the conclusion
that LPS is a suitable model for studying the impact of new therapies for acute systemic
inflammation (Seemann et al., 2017). But importantly, this endotoxin is produced by the
gut microbiota in response to systemic infections, and its subsequent release in the
systemic circulation plays a key role in the development and persistence of systemic
inflammation (Maldonado et al., 2016; Thorburn et al., 2018). Circulating LPS levels are
elevated in AD patients (Zhang et al., 2009) and the recent discoveries of LPS infiltration
in the post-mortem AD brain where it associates with Aβ plaques, highlights the clinical 
relevance of this immune model (Zhan et al., 2018; Zhan et al., 2016; Zhao et al., 2017).
This has led to the proposal that endogenous LPS accumulation could play a critical role in
the pathophysiology of the common, sporadic form of AD (Pistollato et al., 2016; Sochocka
et al., 2019; Zhan et al., 2018). To the best of our knowledge, endogenous LPS levels
have not been quantified in AD models. Differences in gut microbiota composition between
genetic models of AD and their wild type control, consistent with endotoxemia and
susceptibility to LPS, have been reported and found associated with the progression of
cerebral amyloidosis (Brandscheid et al., 2017; Harach et al., 2017; Zhang et al., 2017).
Removal of microbiota from a humanized AD model delayed substantially Aβ plaque 
deposition, while colonisation of these mice with gut microbiota from a conventional AD
model, but not from their wild type control, accelerated Aβ deposition (Harach et al., 
2017). There is, therefore, a need to better understand the mechanisms whereby systemic
LPS affects the brain and contributes to AD progression.
LPS, is an agonist of the toll-like receptor 4, which in the brain, is almost exclusively
expressed by microglia (Hanke and Kielian, 2011), the resident immune cell in the central
nervous system. Microglia play a critical role in the clearance of Aβ and tau aggregates, 
and their dysfunction is associated with the genetic risk of developing AD (Hansen et al.,
2018; Perea et al., 2018). At low doses able to induce physiologically relevant low grade
inflammation, penetration of LPS in the mouse brain is limited in the absence of blood
brain barrier dysfunction (Banks and Robinson, 2010; Varatharaj and Galea, 2017).
However, pro-inflammatory changes in microglia can be seen as early as 4 hours post-
inoculation depending on the disease status (Murray et al., 2011; Pardon et al., 2016).
Using magnetic resonance spectroscopy, we previously observed that mild systemic
inflammation, induced with the low 100µg/kg dose of LPS, rapidly altered hippocampal
metabolism in the APPswe/PS1dE9 (APP/PS1) mouse model of amyloidosis and its wild-
type (WT) littermates at early to advanced pathological stages (Pardon et al., 2016). The
metabolic changes occurring within 4 hours of immune stimulation also discriminated the
microglial response of WT and APP/PS1 mice (Pardon et al., 2016). Variations in brain
metabolism and substrate availability are thought to influence microglial function, although
the mechanisms involved are not clear (Ghosh et al., 2018). In the same APP/PS1 mouse
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perturbations have been reported in the brain of males and females, but sex differences
have not been systematically tested (Gonzalez-Dominguez et al., 2014; Maroof et al.,
2014), although they have been seen with brain aging in WT mice and are thought to
contribute to differential susceptibility to AD-like pathology (Zhao et al., 2016). Preclinical
data from genetically altered mouse models of AD indeed confirm that cerebral amyloidosis
indeed develops faster in females than in males (Li et al., 2016; Wang et al., 2003). Thus,
metabolic responses to systemic inflammation could mediate exacerbation of AD-like
pathology and the impact of sex on disease progression.
In this context, we aimed, in the present study, to gain further understanding of
the metabolic processes occurring at onset of systemic inflammation with LPS, and used
untargeted metabolomics to comprehensively identify pathways that rapidly respond to
immune stimulation in WT and APP/PS1 mice of both sexes. We tested the hypothesis that
APP/PS1 mice would be more susceptible to the metabolic effects of LPS, and postulated
a sexual dimorphism in the hippocampal metabolic response to systemic inflammation. As
reviewed above, systemic inflammation is expected to be an early event in the
pathogenesis of AD; we therefore used 4.5-month-old mice, an age characterised by the
appearance of the first plaques and subtle cognitive deficits (Bonardi et al., 2011; Malm
et al., 2011; Maroof et al., 2014). Our results indicate that pathways regulating energy
metabolism, immune and oxidative stress responses are simultaneously recruited 4 hours
after systemic LPS, and comparably in the hippocampus of both WT and APP/PS1 mice,
whose hippocampal metabolism was similar in the absence of immune stimulation. While
unchallenged females exhibited a pro-inflammatory and pro-oxidant hippocampal
metabolic signature compared to males, the recruitment of some pathways at onset of
systemic inflammation was sex-dependent with the metabolic response of females shifting
towards a more pronounced anti-inflammatory and neuroprotective component than
males, which also showed more severe sickness symptoms at this time point.
2. Material and methods
2.1. Ethics statement
All procedures were carried out in accordance with the UK Animals (Scientific
Procedures) Act of 1986 under project license 40/3601, approved by the University of
Nottingham Ethical Review Committee and are reported according to the ARRIVE
guidelines (Kilkenny et al., 2010). All analyses were performed in blind.
2.2. Animals
6Forty-four 4.5-month-old male and female APPswe/PS1dE9 (APP/PS1, (Jankowsky
et al., 2004)) mice and their wild-type (WT) littermates were used (n=5-6 per sex,
genotype and treatment). All experimental animals were bred and maintained in the
University of Nottingham Biomedical Service Unit as previously described (Pardon et al.,
2016). Genotyping was performed by Transnetyx (Cordova, TN, USA). Mice were
maintained group-housed in individually vented cages (3-4 per cage) under standard
husbandry conditions with ad libitum access to food and water, and were provided with
nesting material and a play tube. The room was on a 12/12 h light cycle with lights on
at 07:00 h; temperature, relative humidity and air exchange were automatically
controlled.
2.3. Drug treatment
Lipopolysaccharide (LPS, Escherichia coli serotype Sigma0111:B4, Sigma
Aldrich) was dissolved in phosphate buffered saline (PBS, Sigma Aldrich) at a
concentration of 200 μg/ml, and stored in aliquots at −20°C until use. On the day of the 
experiment, LPS was further diluted 1:2 in PBS to a final concentration of 100 μg/ml. 
Mice were injected intravenously (i.v.) in the lateral tail vein with 100 μg/kg of LPS, or 
an equivalent volume of its vehicle PBS, as previously described (Pardon et al., 2016).
2.4. Study design
The timeline of the experiment is represented in Fig. 1A. 4.5-month-old male and
female APP/PS1 and WT mice were randomly allocated to the LPS or PBS treatment groups
(n=5-6). Baseline behavioural assessment was carried out on days 1 & 2. Mice were first
tested for spatial working memory performance and exploratory drive in the spontaneous
alternation test (Day 1). They were then trained to burrow food in groups overnight in
their home cage (Deacon, 2012) and on Day 2, underwent baseline food burrowing testing
over 4 hours while singly housed. On Day 3, mice were challenged with LPS (100μg/kg 
i.v.) or PBS (1μl/g of body weight). Post-treatment sickness effects were assessed 4 hours 
after injection in the food burrowing and spontaneous alternation tests, by monitoring
changes in body weight and assessing body temperature taken using a rectal probe at the
time of culling. Immediately after the spontaneous alternation task, mice were culled by
cervical dislocation and trunk blood was collected. Their brains were removed; the
hippocampi were dissected from one hemisphere, snap frozen and stored at -80°C until
use for metabolomics. The second hemisphere was post-fixed by immersion in 4%
paraformaldehyde, stored at 4–8 °C for a minimum of 24 hours, and then embedded in
paraffin wax on a tissue embedding station (Leica TP1020).
72.5. Behavioural assessment
2.5.1. Food Burrowing
Food burrowing is a species-specific behaviour largely, dependent of the integrity
of the hippocampus (Deacon et al., 2002), which is suppressed in response to systemic
inflammation (Teeling et al., 2007). The protocol was adapted from one previously
described (Geiszler et al., 2016). A glass jar containing 30g of food pellets broken into
small pieces was added to the home cage overnight for training in groups, or in individual
cages for the two test sessions, with ad libitum access to food and water. The amount of
food displaced from the jar was recorded, expressed as a percentage from the 30g
provided, and used as a measure of food burrowing performance. To assess sickness
effects, the difference between pre- and post-injection burrowing performance was
calculated.
2.5.2. Spontaneous Alternation
Spontaneous alternation was used as previously described (Geiszler et al., 2016;
Maroof et al., 2014) to assess spatial working memory and exploratory drive. The latter is
suppressed in response to LPS-induced sickness and is a potential confounding factor for
the assessment of cognitive effects (Cunningham and Sanderson, 2008). The Y-shaped
maze comprised three identical transparent Plexiglas® arms at a 120° angle from each
other (41.5 cm in length and 6 cm in width surrounded by 15 cm high transparent Perspex
walls). The start point (6 cm x 7.5 cm) was located in the center of the maze, and the
mice were allowed to freely explore the three arms over five minutes. The number of
alternations was recorded manually and expressed as a percentage of alternations to
estimate spatial working memory performance, while the number of arms visited was used
as an indication of exploratory drive. To assess sickness effects, the difference between
pre- and post-injection performance was calculated. Mice that entered only one arm after
the LPS challenge (1 WT female, 1 WT male and 2 APP/PS1 males) were excluded from
sickness data as their alternation rate post-injection could not be calculated, but remained
included in the analysis of baseline performance.
2.6. Immunohistochemical analyses
2.6.1. Immunohistochemistry
7 μm-thick coronal sections were cut throughout the hippocampus using a 
microtome (Microtome Slee Cut 4060), mounted on APES-coated slides and dried
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adaptor molecule 1 (Iba1) and the astrocyte marker glial fibrillary acidic protein (GFAP)
was carried out using standard protocols as previously described (Pardon et al., 2016),
in 6-8 brain slices per brain. Incubation with rabbit anti-Iba1 [Wako, cat. nr. 019–19741;
1:6000 in PBS-Tween (0.05% Tween-20 in PBS)] or anti-GFAP (Biogenix, cat. nr.
AM020-5M, 1:4000 in PBS-T) antibodies was carried out for 1 h at room temperature.
Biotinylated secondary antibody (Vectastain Elite ABC Kit, Rabbit IgG, Vector Labs,
Burlingame, CA cat. nr. PK-6101, 1:200 in PBS-T) was applied for 30 min. Tissue was
washed, exposed to ABC-HRP (Vectastain Elite ABC Kit R.T.U, Vector Labs, cat. nr. PK-
7100), labelled with DAB peroxidase substrate (Vector Labs cat. SK-4100) according to
manufacturer’s instructions, and counterstained using a haematoxylin and eosin
protocol. Digital focused photo-scanning images were then acquired using a Hamamatsu
NanoZoomer-XR 2.0-RS C10730 digital scanning system with TDI camera technology a
NanoZoomer (Hamamatsu Photonics K.K. Systems, Japan) at 20× magnification and
visualised using NDP.view2 (NanoZoomer Digital Photography).
2.6.2. Semi-automated quantification of Iba1 and GFAP immunostaining
For segmentation of microglia and astrocytes, and extraction of microglial
morphometric features, we used custom made software (Matlab) adapted from our
previous studies (Ding et al., 2016; Pardon et al., 2016) and applied to the following
regions of interest: whole hippocampus, hippocampal CA1, CA2, CA3 and dentate gyrus
(DG) subfields. Examples of the semi-automated extraction of regions of interest selection
are shown in Suppl. Fig. 5A. This provided the percentage area occupied by glial cells,
the number of Iba1- and GFAP- positive cells, used as a measure of microglial and
astrocyte density, respectively, and the size of microglial soma, used as a morphometric
marker of microglia activation and known to be sensitive to LPS (Kozlowski and Weimer,
2012; Kreisel et al., 2014; Pardon et al., 2016).
2.7. Multiplex
Plasma levels of interleukin 1 beta (IL-1β), IL-6, IL-10, interferon gamma (IFN-γ) 
and tumour necrosis factor alpha (TNF-α) were determined using the Bio-Plex ProTM 
Mouse Cytokine 23-Plex, Group I assay and Bio-Plex array reader, and analysed using the
Bio-Plex Manager Software (Bio-Rad Laboratories, Berkeley, CA, USA) according to the
manufacturer’s instructions. The cytokine panel was designed to provide a measure of key
cytokines known to respond to LPS and to play a role in AD. IL-1β data were deemed 
unreliable and were excluded from the results section.
2.8. Mass spectrometry
92.8.1. Metabolomic profiling by LC-MS
Hippocampal tissues were weighed and then homogenised with
chloroform/methanol/water (1:3:1, 10 µl/mg) using Retsch MM301 ball mill equipment for
3 min. The extraction solvent and sample rack for the ball mill were pre-cooled at -20 C.
The homogenised tissues were mixed vigorously for 1 h at 4 C and then centrifuged at
15,000g for 10 min at 4 C. After centrifugation, the supernatant was collected and stored
at -80 C prior to LC-MS analysis. A quality control sample was prepared by mixing an
equal volume of all samples in order to assess instrument performance (Pereira et al.,
2010). Chromatographic separation was performed using a ZIC-pHILIC column (150 mm
 4.6 mm, 5 µm, Merck Sequant). The column was maintained at 45 C with a flow rate of
300 µl/min as previously described (Surrati et al., 2016). Briefly, the mobile phase
consisted of 20 mM ammonium carbonate in water (A) and 100% acetonitrile (B), and the
tissue extracts were eluted with a linear gradient over 24 min as follows: 80% B (0 min)
to 5% B over 15 min to 5% B with a 2 min linear gradient, followed by re-equilibration
with 80% B. A 10 µl injection of each extract was employed for LC-MS analysis. An Exactive
MS (Thermo Fisher Scientific, Hemel Hempstead, UK) was used to acquire spectral data in
full scan (m/z 70-1400, resolution 50 000) and both positive and negative electrospray
ion modes. The capillary temperature and probe temperature were maintained at 275 and
150 C, respectively as previously described (Creek et al., 2011).
2.8.2. LC-MS data processing
XCMS was used to pre-process raw LC-MS data for untargeted peak-picking
(Tautenhahn et al., 2008) and mzMatch was employed for peak matching and annotation
of related peaks (Scheltema et al., 2011). The processed data was then imported into
IDEOM for noise filtering and putative metabolite identification (Creek et al., 2012).
Metabolite identification was carried out by matching accurate masses and retention times
of authentic standards but when standards were not available, accurate masses and
predicted retention times were used (Sumner et al., 2007). Metabolites were filtered in
IDEOM to have retention time errors of below 35% and mass errors below three parts per
million (Vincent et al., 2014).
2.9. Data analysis
Data are presented as mean ± SEM (standard error of the mean) and were analysed
using InVivoStat (Clark et al., 2012), unless otherwise stated. Baseline behavioural and
body weight data, sickness scores, histological and cytokine data were all subjected to 3-
way ANOVAs with genotype, sex and treatment, followed, where appropriate, by planned
comparisons. To assess the effect of the PBS and LPS challenges on behavioural data and
to compare baseline and post-injection data, we used 3-way ANOVAs with genotype, sex
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and treatment and repeated measure over time, followed, when appropriate, by planned
comparisons. The following pairwise comparisons were decided a priori: i) PBS-treated WT
vs APP/PS1 mice within each sex to test for genotype differences; ii) PBS-treated males
vs females within each genotype to test for sex differences; ii) PBS- vs LPS-treated mice
within each sex and genotype condition to test for differences caused by systemic
inflammation with LPS and, where appropriate, iv) baseline vs post-injection data within
each experimental group to test for the effect of the PBS or LPS challenge. Cytokine and
food burrowing data were rank-transformed to normalise the distribution, but presented
as non-normalised responses (Deacon, 2012). The number of arm entries was used as a
covariate for the analysis of spontaneous alternation performance, in order to control for
confounding effects of LPS-induced behavioural suppression.
For LC-MS data, variable selection was performed as a by-product of a classification
model. Data were first subjected to multivariate analyses by principal component analysis-
class (PCA) and orthogonal partial least squares-discriminant analysis (OPLS-DA), using
SIMCA-P version 15.02 (Umetrics AB, Umea, Sweden), in order to detect global metabolic
differences between experimental conditions. This was followed by OPLS-DAs applied to
models including 2 classes: i) WT vs APP/PS1 PBS-treated mice, to identify potential
metabolic differences due to the genotype in the absence of immune stimulation, ii) male
vs female PBS-treated mice, to identify sex-dependent metabolic differences; iii) LPS vs
PBS for all mice to identify effects global effects of LPS; iv) LPS vs PBS for each sex
separately to identify sex-dependent metabolic responses to LPS. Mass ions which
contributed to separations and clusters were selected according to the variable importance
in projection (VIP), a weighted sum of the PLS weight which indicates the importance of
the model. VIP values greater than 1.5 were first considered indicative of significant
differences between groups. Next, these metabolites were subjected to three-way ANOVAs
with genotype, sex and treatment as between subject factors, to confirm the statistical
significance of these factors and test for significant interactions between them. Metabolites
from this list for which significant overall effects of treatment, or sex X treatment
interaction were found, were also considered as potential discriminant of the LPS response
within each sex if VIP values from the OPLS-DA models testing the effect of LPS within
each sex were greater than 1. This was followed, where appropriate, by planned
comparisons, as defined above.
Relationships between behavioural, cytokine, glial and metabolic data, and
whether these associations were dependent upon the genotype, sex or treatment, were
tested using the Pearson correlation coefficient, for which statistically significant values
above 0.7 were considered as strong associations.
P ≤ 0.05 was considered statistically significant for all analyses. 
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3. Results
3.1. Systemic LPS-induced sickness
To assess whether APP/PS1 mice responded more strongly to LPS in the early hours
after systemic injection than their WT littermates, and to explore the sex dependency of
this response, we assessed LPS-induced sickness using physiological measures and by
monitoring behavioural suppression from baseline pre-injection performance in two tasks.
Results of the three-way ANOVAs on these measures are presented in Suppl. Table 1.
3.1.1. Body mass and rectal temperature
Body mass was overall lower in females regardless of their genotype (F(1,36) =
152.67, p=0.005; Suppl. Fig 1A). Within APP/PS1 mice, females (p<0.0001), but not
males (p=0.87), weighed less than their WT littermates (Genotype x Sex: F(1,36) = 12.22,
p=0.0013) but none of the experimental groups showed significant weight loss 4 hours
after the LPS or PBS challenge (Suppl. Fig 1A). Rectal body temperature was overall
reduced by LPS (F(1,34)=17.09, p=0.0002), but partial comparisons showed that this
decrease was only significant in males (minus ~1.2-1.5°C, p<0.05 for both WT and
APP/PS1 males compared to PBS-treated males, Fig. 1B).
3.1.1. LPS suppressed food burrowing activity
Food borrowing behaviour was overall suppressed by systemic LPS (p<0.0001) but
unaffected by PBS (p=0.52; Treatment x Time: F(1,36)=9.47, p=0.004, Fig. 1C). Significant
reductions in food burrowing behaviour 4 hours after injection of LPS were seen in WT
males (p=0.008), WT females (p=0.002) and APP/PS1 females (p=0.04), but not in
APP/PS1 males (p=0.10) whose baseline performance was lower than of WT males females
and more variable than of APP/PS1 females (Fig. 1C).
3.1.2. LPS suppressed exploratory drive without altering spatial working memory
performance
Exploration of the Y maze, assessed through the number of arm visits, did not differ
between any experimental groups at baseline (Fig. 1D) but was suppressed by LPS,
regardless of the genotype (p<0.0001 compared to baseline in all cases, Fig. 1E, and
p<0.01 compared to PBS-treated mice in all cases, Suppl. Fig 1B; Treatment:
F(1,36)=20.66, p<0.0001). All PBS-treated groups, but female APP/PS1, also showed a
milder reduction in Y maze exploration 4 hours after injection (p<0.05 in all cases, Fig.
1E; Treatment x Time: F(1,36)=58.55, p<0.0001), reflecting habituation to the apparatus.
Spontaneous alternation performance was overall lower in females compared to males
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(F(1,35)=4.25, p=0.048, Fig. 1F) at baseline but not following PBS or LPS administration
(Suppl. Fig 1B), and none of the treatments altered the alternation rate (Fig. 1G).
3.2. Systemic LPS-induced circulating cytokines
We assessed systemic inflammation 4 hours after inoculation with LPS by
quantifying plasma levels of 5 pro- or anti-inflammatory cytokines. Results of the three-
way ANOVAs applied to circulating cytokine levels are presented in Suppl. Table 2.
We found that, regardless of sex and genotype, LPS led to significant increases in
plasma levels of IL-6 (F(1,30)=116.2, p<0.0001, post-hoc tests: p<0.0002 compared to
PBS-treated mice in all cases, Fig. 2A), a cytokine known to exert both pro-and anti-
inflammatory effects. Elevated levels of the pro-inflammatory cytokine TNF-α after LPS 
(F(1,30)=7.82, p=0.009) were only significant in WT females (p=0.02 compared to PBS-
treated mice, Fig. 2B), whereas LPS-treated females also exhibited significantly higher
levels of the anti-inflammatory cytokine IL-10 (Treatment x Sex: F(1,30)=4.54, p=0.04),
regardless of their genotype (WT: p=0.0004 and APP/PS1: p=0.007, compared to PBS-
treated mice, Fig. 2D). Circulating INF-γ (F(1,30)=2.70, p=0.11, Fig. 2C) levels were
unaltered by LPS.
3.3. Hippocampal metabolic profiles
3.3.1. Identification of discriminant metabolites
To investigate LPS-induced metabolic changes in the hippocampus, and whether
this was dependent upon the genotype and/or and sex of the mice, we used LC-MS
analysis. Metabolic data from all hippocampal extracts were first subjected to PCA, to
identify trends, and OPLS-DA to detect global metabolic differences between experimental
conditions. Then, OPLS-DAs applied to models including 2 classes were carried out in order
to identify metabolites differentially expressed in response to LPS or as a function of sex
or genotype. The quality of these models was assessed by the R2 and Q2 parameters which
indicate the variance explained by the model and predicted variance after cross-validation,
respectively and range between 0 and 1, with Q2 values above 0.5 (50% of variance
predicted) revealing good separation between the classes tested.
Metabolites were considered to contribute to the separations and clusters
associated with each experimental condition when their VIP values from OPLS-DA models
was greater than 1.5 if subsequent 3-way ANOVAs confirmed their ability to discriminate
genotypes, sexes, treatment conditions and/or interactions between these factors. As
shown in Table 1, 98 metabolites were identified as potential discriminators of the disease
status, sex and/or LPS response, after confirmation with ANOVAs. Their function in the
brain and potential implication in sex differences in brain function, AD progression and/or
inflammatory processes, when known, is presented in Suppl. Table 3.
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3.3.1.1. Global metabolic differences reveal distinct clustering between PBS- and LPS
treated mice
PCA analysis preformed on all animals gave 6 components explaining 59.6% of the
variance. The plots pertaining to the first two components revealed, as the major trend, a
separation between LPS-treated males and females (Fig. 3A). This was confirmed by the
global OPLS-DA which gave 5 components (1 predictive and 4 orthogonal) with a variance
explained (R2) of 99.4% and predictive variance (Q2) of 88.6%. As shown on Fig.3B a
clear separation was found between PBS- and LPS-treated male and female WT and
APP/PS1 mice 4 hours after the immune challenge, indicating that metabolic changes
rapidly occurred in response to LPS, regardless of sex or disease status. Within LPS-treated
mice, some separation between sexes was also seen, regardless of genotype (Fig. 3B),
suggesting that the response to LPS was in part, sex-dependent. Metabolic differences
between genotypes were not apparent. Thirty-seven metabolites with VIP values above
1.5 were identified from the global OPLS-DA model. Thirty-two of them showed statistically
significant overall effects of treatment, revealing major changes in amino acids,
carbohydrate, nucleotide, lipid and energy metabolism in response to LPS, regardless of
sex and genotype (Table 1).
Subsequent 2-class OPLS-DAs between PBS- and LPS-treated mice within each sex,
also gave strong models with a variance explained of 100% and a predicted variance above
85%. Five components were identified in males (1 predictive + 4 orthogonal; R2= 1.00,
Q2 = 0.857) and 7 in females (1 predictive and 6 orthogonal; R2= 1.00, Q2 = 0.863).
Loading plots of predictive vs first orthogonal components revealed a clear separation
between treatment groups, regardless of genotype, in both sexes (Fig. 3C&D, for males
and females, respectively). The hippocampal metabolic response of males to LPS was
characterised by significant changes in 53 metabolites (Table 1). Thirty-six discriminant
metabolites with VIP values above 1.5 were identified from the 2-class OPLS-DA between
PBS- and LPS-treated males, and confirmed with ANOVAs. Statistical significance between
these groups was also confirmed for another 13 metabolites identified from the global
OPLS-DA model, and for 4 the 11 metabolites with confirmed Sex X Treatment interaction
effects. The hippocampal metabolic response to LPS in females was characterised by
statistically significant changes in 50 metabolites (Table 1). Twenty discriminant
metabolites with VIP values above 1.5 were identified from the 2-class OPLS-DA model,
and confirmed with ANOVAs. Statistical significance between PBS- and LPS-treated
females was also confirmed for another 20 metabolites identified from the global OPLS-
DA model, and for 9 of the 11 metabolites showing sexually dimorphic responses to LPS.
3.3.1.2. Discriminant metabolites between sexes in PBS-treated mice
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Since the metabolic response to LPS was found to be, at least in part, sex-
dependent, a 2-class OPLS-DA was also carried out between PBS-treated males and
females in order to identify whether the hippocampal metabolic profile of males and
females differs in the absence of immune stimulation. This gave a strong model with 1
predictive and 2 orthogonal components (R2= 0.985, Q2 = 0.809) and clear separation
between sexes, regardless of genotype (Fig. 3E). Sex differences in hippocampal
metabolism were characterised by significant changes in the levels of 40 metabolites,
showing major differences in amino acids, carbohydrate and fatty acyls metabolism (Table
1). While forty-three metabolites with VIP values above 1.5 were identified from the 2-
class OPLS-DA model, 36 were confirmed with statistically significant sex effects in PBS-
treated mice. Sex differences in PBS-treated mice were also confirmed for another 4
metabolites for which significant effects of sex or sex X treatment interaction were
revealed by individual ANOVAs.
3.3.1.2. Lack of major metabolic perturbations in the hippocampus of 4.5-month-old
APP/PS1 mice
Next we carried out a 2-class OPLS-DA between genotypes in PBS-treated mice to
confirm the lack of apparent differences in the hippocampal metabolic profile of WT and
APP/PS1 mice. This gave a weak model explaining 24.4% of the variance between
genotypes (3 predictive, 0 orthogonal components; R2= 0.697, Q2 = 0.244), revealing a
lack of complete separation between WT and APP/PS1 mice (Fig. 3F). This indicates that
the metabolic profile of PBS-treated WT and APP/PS1 mice was not strongly influenced by
the disease status, consistent with our previous study in males showing a lack of clear
differences in hippocampal metabolism between WT and APP/PS1 mice at 4 and 8 months
of age (Maroof et al., 2014).
Accordingly, only 2 metabolites with VIP values above 1.5 could be identified with
this 2-class OPLS-DA model and confirmed with ANOVAs. Significant genotype effects were
also found for another 3 out of the 98 validated metabolites, with confirmed statistical
significance within PBS-treated mice (Table 1). Although some separation in hippocampal
metabolism appear to be emerging between 4.5-months-old WT and APP/PS1 males (Fig.
3F), statistically significant genotype differences were predominantly seen in females
(Suppl. metabolomics results and Suppl. Fig. 2). This apparent distinct clustering, which
cannot be explained by orthogonal variation within males, may be due to a combination
of borderline differences that are not sufficiently severe to reach statistical significance in
individual ANOVAs. Indeed, 59 additional metabolites showed VIP values comprised
between 1 and 1.5 (Table1).
3.3.2. Metabolic pathways with sex differences and responsive to systemic LPS
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The analyses revealed that regardless of sex and disease status, LPS predominantly
affected the activity of four metabolic pathways: tryptophan (Fig. 4) and methionine (Fig.
5), regardless of sex and disease status, pyruvate in males (Fig. 6) and methylglyoxal in
females (Fig. 7); while sex differences were also found in the absence of immune
stimulation within the methionine (Fig. 5) and pyruvate (Fig. 6) metabolic pathways.
Changes in other metabolites as well as their role in brain function and implications
in sex differences, AD progression and immune processes, are reported in Suppl.
metabolomics results, Suppl. Fig. 3 and Suppl. Table 3, respectively.
3.3.2.1 LPS-induced tryptophan metabolism regardless of sex and disease status
Tryptophan metabolic pathways are represented Fig.4. Tryptophan is an essential
amino acid involved in protein synthesis and substrate of a number of bioactive
substances. It is the precursor of the monoaminergic neurotransmitter serotonin which
plays a critical beneficial role in modulating behaviour, cognition, mood, stress and
inflammatory responses (Hoglund et al., 2019). The majority of tryptophan is, however,
catabolised by the kynurenine pathway, the first part of the tryptophan nicotinamide
pathway (Fukuwatari and Shibata, 2013), which has been linked to impaired behavioural
and stress responses, and proinflammatory changes to the brain (Hoglund et al., 2019).
Kynurenine metabolism leads to activation of nicotinamide adenine dinucleotide (NAD)
metabolism, an important regulator of various energy metabolism pathways and cellular
homeostasis, via the biosynthesis of quinolinic acid, forming the second part of the
tryptophan-nicotinamide pathway (Fukuwatari and Shibata, 2013; Yaku et al., 2018).
Both the serotonin and nicotinamide pathways of tryptophan metabolism,
illustrated Fig. 4, were found to be stimulated in the hippocampus of LPS-treated mice.
This was reflected by elevated L-tryptophan levels (Fig. 4A), associated with higher levels
of 5-Hydroxylindoleacetate (5-HIAA), the end product of the serotonin pathway of
tryptophan metabolism, as well as of N1-methyl-2-pyridone-5-carboxamide (2PY, Fig.
4B&C), a toxic degradation product of nicotinamide (Lenglet et al., 2016) whose levels
reflect the amount of nicotinamide biosynthesized from tryptophan (Shibata and Matsuo,
1990) and correlate with upstream activation of the kynurenine pathway of tryptophan
metabolism (Mayneris-Perxachs et al., 2016).
Correlation analyses indicated that fluctuations in 2PY levels were associated with a
number of parameters related to the sickness response to LPS. We found negative
associations between 2PY levels and i) rectal temperature (Fig. 4D) in males, which
exhibited LPS-induced hypothermia (males: r = -0.718, p = 0.0004; females: r = -0.21,
p = 0.37); ii) the number of arms visited in the spontaneous alternation test 4 hours
after the injection (r = -0.80, p < 0.0001; Fig. 4E), in both males (r = -0.837,
p < 0.0001) and females (r = -0.791, p < 0.0001); and iii) sickness scores for arm visits
16
(r = -0.773, p < 0.0001; Fig. 4F) in both males (r = -0.741, p < 0.0001) and females
(r = -0.824, p < 0.0001).
3.3.2.2. LPS-induced alterations in methionine metabolism are in part sex-dependent
Methionine is an essential amino acid involved in protein synthesis and required for
growth and tissue repair, immune responses, protection against oxidative stress as well
as epigenetic regulation in the brain (Martinez et al., 2017; McGowan et al., 2008). It is
also a substrate for other key amino acids, such as taurine and cysteine, as well as the
antioxidant molecule glutathione (Fig. 5).
Significant reductions in L-methionine (Fig. 5A), L-methionine S-oxide (Fig. 5B), a
toxic oxidation product of methionine (Stadtman et al., 2005), and 5’-methylthioadenosine
(Fig. 5C), a methionine precursor in the salvage pathway (Christa et al., 1986), indicated
that LPS attenuated the production and metabolism of L-methionine, regardless of sex and
disease status.
Levels of S-adenosy-L-homocysteine, an intermediate in methionine biosynthesis
and degradation by the recycling and transsulfuration pathways, respectively, were
increased by LPS in APP/PS1 males with opposite effects seen in APP/PS1 females
(Genotype X Sex X Treatment: F(1,34)=4.13, p=0.49; Fig. 5E). Methionine is a substrate
for the anti-oxidant molecule glutathione whose toxic oxidation product glutathione
disulfide (Stadtman et al., 2005) was more found more abundant in the hippocampus of
LPS-treated males, regardless of genotype, but less abundant in the hippocampus of WT
females (Sex X Treatment: F(1,34)=14.52, p=0.0006, Fig. 5H).
Effects of LPS were more pronounced in females which also showed downregulation
of other metabolites involved in the synthesis of methionine via both the salvage and
recycling pathways. LPS-treated females exhibited reduced hippocampal levels of S-
adenosy-L-methionine (Fig. 5D), an intermediate in methionine salvage also involved in
the synthesis of homocysteine, key intermediate in methionine metabolism located at the
branch point between the recycling pathway and transsulfuration pathway, as well as of
O-succinyl-L-homoserine (Fig. 5F), also involved in L-methionine recycling and
degradation via modulation of homocysteine biosynthesis (Flavin and Slaughter, 1967).
In the absence of immune stimulation, females also presented with reduced levels
of L- 5’-methylthioadenosine (Fig. 5C), the first step in the methionine salvage pathway,
as well as L-cystathionine and hypotaurine (Fig. 5G&I, respectively), two methionine
derivatives and key intermediates in the synthesis of taurine, an amino acid found in very
high concentrations in most cells (Schaffer and Kim, 2018); but L-methionine levels were
not affected by sex differences (Fig. 5A).
3.3.2.3. LPS lowers pyruvate metabolism in APP/PS1males
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Pyruvate is a key metabolite in several metabolic pathways important for glucose
and energy homeostasis, with potent anti-oxidant and anti-inflammatory properties (Das,
2006). It is made from glucose and is the end-product of glycolysis (Fig. 6).
In males, and more specifically APP/PS1 males, LPS rapidly lowered pyruvate
metabolism by downregulating several intermediates in the glycolysis pathway. D-fructose
1,6-bisphosphate (Fig.6A), and downstream metabolites, D-glyceraldehyde 3-phosphate
(Fig.6B), 3-Phospho-D-glycerate (Fig. 6C), phosphoenolpyruvate (Fig. 6D) and ultimately
of pyruvate (Fig. 6E) were all significantly less abundant in the hippocampus of LPS-treated
APP/PS1 males 4 hours after LPS administration. A baseline, however, there was a trend
for these metabolites to be more abundant in the hippocampi of APP/PS1 males, explaining
the greater effect of LPS, but post-LPS levels of these intermediates in pyruvate
metabolism were similar in males from both genotypes. This was associated with reduced
levels of 2-phosphoglycolate (Sex X Treatment: F(1,34)=7.63, p=0.009, Fig. 6G), which can
be converted into the glycolytic intermediate 3-phospho-D-glycerate (Fig. 6C) via
activation of glycolate metabolism. Conversion of glucose into fructose is a two-step
process in which glucose is reduced to sorbitol, which is then converted to fructose. LPS-
treated APP/PS1 males also failed to show the decreased in D-sorbitol contents observed
in all other LPS-treated groups (WT males, WT and APP/PS1 females, Fig.6F). In females
of both genotypes, LPS also reduced the levels of S-malate (Sex X Treatment:
F(1,34)=11.62, p=0.0017, Fig. 6I), a metabolite of the KREBS cycle, which can be recycled
into pyruvate.
3.3.2.4. LPS lowers methylglyoxal metabolism in females
Methylglyoxal is a neurotoxic by-product of glycolysis, fructose, fatty acid and
protein metabolism and potent inducer of inflammation and oxidative stress which can be
detoxified by degradation in D-lactate via conversion into D-S-lactoylglutathione [(Allaman
et al., 2015; Desai et al., 2010), Fig. 7].
In females, LPS induced a downregulation a number of metabolites upstream and
downstream of methylglyoxal production. This includes D-sorbitol, which is involved in
fructose metabolism (Fig.6F), metabolites involved in the biosynthesis of unsaturated fatty
acids, particularly APP/PS1 females [hexadecanoic acid, octadecanoic acid, icosatrienoic
acid (Sex X Treatment: F(1,34)=10.67, p=0.002), Fig. 7A-C, respectively], the fatty acid
and conjugate [FA (20:4)] 5Z,8Z,11Z,14Z-eicosatetraenoic acid (Sex X Treatment:
F(1,34)=11.42, p=0.0018, Fig. 7D) as well as sn-glycerol 3-phosphate (Sex X Treatment:
F(1,34)=10.94, p=0.002, Fig. 7E), which is synthesised by both glycerol and sn-glycero-3-
phosphoethanolamine (Sex X Treatment: F(1,34)=18.49, p=0.002, Fig. 7F) to form
dihydroxyacetone phosphate and ultimately, methylglyoxal. This was associated with
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reduced levels of its degradation product (D)-S-lactoylglutathione and (D)-lactate (Sex X
Treatment: F(1,34)=6.17, p=0.02 & F(1,34)=5.62, p=0.02; Fig. 7G&H, respectively).
3.4. Lack of glial response to LPS at 4 hours post-injection
We used immunohistochemistry to detect Iba-1 positive cells, quantify their
number, the area they occupied and the size of their soma (used as a morphological
marker of microglial activation) and to determine the area occupied by GFAP-positive
astrocytes, in the hippocampus of 4.5-month-old male and female WT and APP/PS1 mice
4 hours after LPS or PBS administration. Results of the three-way ANOVAs applied to these
measures are presented in Suppl. table 4.
We report that the area occupied by Iba-1 positive microglia was lower in the
hippocampus of WT female mice compared to WT males and APP/PS1 females (Genotype
X Sex: F(1,35)=4.14, p=0.049, Fig. 8A&F), with significant reductions being particularly
evident in the CA2 (Genotype X Sex: F(1,34)=4.24, p=0.047, Fig. 8C&H) and CA3 (Genotype
X Sex: F(1,36)=7.37, p=0.01, Fig. 8D&I) subfields. The smaller area covered by microglia
seen in WT females was particularly evident in PBS-treated mice for both the whole
hippocampus (p =0.02 vs WT males and APP/PS1 females, Fig. 8F) and CA3 subfield
(p=0.01 vs WT males and p=0.007 APP/PS1 females, Fig. 8I). LPS caused non-significant
reductions in the area covered by Iba-1 throughout the hippocampus of APP/PS1 females,
as well as of males from both genotypes (Fig. 8F-J). We also found a lower number of Iba1
positive cells in the DG of PBS-treated females compared to PBS-treated WT males
(p=0.008, Fig. 8O) and APP/PS1 females (p=0.03, Genotype X Sex: F(1,36)=5.02, p=0.03,
Fig. 8O). The area of microglial somas did not differ between the sex, genotype and
treatment conditions in any of the hippocampal subfields (Suppl. Fig 5B-F), and there were
very few microglial clusters, albeit significantly more in the hippocampi of APP/PS1 mice
compared to their WT littermates (F(1,35)=10.05, p=0.003; Suppl. Fig 5G), consistent with
the relatively low Aβ plaque load at 4.5 months of age (Suppl. Fig 5H&I). 
We did not detect differences in the area occupied by GFAP after LPS in discrete
hippocampal regions of 4.5-month-old male and female WT and APP/PS1 mice and there
was no genotype or sex dependency in this measure (Suppl. Fig 6A-J).
4. Discussion
Given the role of systemic inflammation in AD pathogenesis and known sex
differences in the risk of AD and immune responses, we tested whether the behavioural
and hippocampal metabolic responses to a systemic challenge with LPS would be
exacerbated in young APP/PS1 female in the early hours post-inoculation. Here, we first
show that the hippocampal metabolic signature of APP/PS1 mice, in the absence of
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immune stimulation, did not clearly differ from that of WT mice, at this early pathological
stage, revealing only subtle differences, but predominantly in females. This is consistent
with our previous study in males (Maroof et al., 2014). Differences in hippocampal
metabolism have been previously reported in this model at 6 months of age, and in
comparison to C57BL/6j mice rather than WT littermates, but without testing for potential
sex differences although both males and females were included in that study (Gonzalez-
Dominguez et al., 2014). Second, we also show in the absence of immune stimulation, a
sexual dimorphism in the hippocampal metabolic profile of 4.5-month-old mice,
particularly affecting methionine and pyruvate metabolism, but independent of the
genotype. The major finding, however, was that 4 hours after onset of systemic
inflammation, several aspects of the LPS response were also sex-dependent. Importantly,
we found at this time point that males and females exhibited comparable behavioural
responses to LPS, regardless of the genotype, but the temperature change was greater in
males and the cytokine response, particularly the secretion of IL-10, was greater in
females. Metabolic data indicated that LPS induced a comparable activation of both the
serotonin and nicotinamide pathways of tryptophan metabolism in the hippocampus of WT
and APP/PS1 mice of both sexes, with hippocampal levels of the toxic nicotinamide
metabolite 2PY being positively associated with the severity of the sickness response. And
while all LPS-treated mice exhibited a downregulation in methionine levels, reversible
oxidation and salvage, sex-differences were observed in the response of the recycling and
transsulfuration pathways of methionine metabolism. Males also exhibited a
downregulation of pyruvate metabolism after LPS, exacerbated in APP/PS1 males, while
females showed downregulation of methylglyoxal metabolism.
Sex differences in hippocampal metabolism in the absence of immune
stimulation
Spontaneous alternation was preserved in APP/PS1 mice regardless of sex, in
agreement with our previous findings in both males and females at the same pathological
stage (Bonardi et al., 2011; Maroof et al., 2014). In the present study, however, we
observed an overall reduction in spontaneous alternation performance in females,
suggesting a lower spatial working memory ability as was also previously reported in
C57BL/6j mice (Tucker et al., 2016), the genetic background of our APP/PS1 mice. Males
are indeed generally found to outperform females for spatial working memory, and this
has been related to differences in hippocampal morphology and function (Koss and Frick,
2017). Accordingly, we have also shown that the hippocampal metabolic profile of females
differed from that of males for 41 metabolites, but similarly in WT and APP/PS1 mice.
The most significant changes affected the metabolism of methionine, an essential
amino acid for protein synthesis and epigenetic regulation in the brain, and key regulator
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of antioxidant protection and immune responses at physiological levels (Martinez et al.,
2017; McGowan et al., 2008). Sex differences were seen in the salvage and
transsulfuration pathways of methionine metabolism, with robustly downregulated levels
of 5’-methylthioadenosine and hypotaurine, respectively. Methionine levels are in part
regulated by the salvage pathway which recycles 5’-methylthioadenosine back in
methionine (Albers, 2009). Reduced levels of 5’-methylthioadenosine in females were not
associated with altered methionine levels, suggesting that they could be maintained via
an alternative biosynthetic route and/or through reduced catabolism. The latter hypothesis
is supported by the associated reduced levels of L-cystathionine and hypotaurine in
females, two key intermediates in the synthesis of taurine from the methionine derivative
homocysteine, during their degradation of via the transsulfuration pathway (Stipanuk and
Ueki, 2011). While methionine levels were preserved in females, the specific changes
observed in downstream metabolites in females may predispose them to immune
dysfunction and cell damage. 5’-methylthioadenosine, is indeed now seen as a key
regulator of immune responses to inflammation and systemic infections (Albers, 2009;
Wang et al., 2017), proven to mediate protection against LPS-induced inflammation in
vitro (Hevia et al., 2004) but also to inhibit inflammation and reduce brain damage in
animal models of neuroinflammation (Moreno et al., 2006). Furthermore, hypotaurine
which has well established antioxidant properties (Fontana et al., 2004), was also found
to effectively suppress inflammatory and neuropathic pain (Hara et al., 2012). Taurine and
hypotaurine are present in elevated levels in the brain of the long-lived Snell Dwarf mouse
(Vitvitsky et al., 2013), which exhibits reduced oxidative damage to the brain (Brown-
Borg, 2006) and hypothalamic inflammation (Sadagurski et al., 2015). Taurine also plays
a protective role against age-related cognitive decline (El Idrissi, 2008), and therefore, the
downregulated transsulfuration pathway of methionine metabolism could, in part,
contribute to the lower spatial working memory performance seen in females.
Increased abundance in members of the glycolytic metabolic pathway, which
provides energy for cellular metabolism in the form of pyruvate and ATP, was also
observed in female hippocampi with particularly elevated levels of 3-phosphoglycerate and
phosphoenolpyruvate in WT females. This was accompanied by unaltered pyruvate and
ATP levels, but reduced levels of 2—phosphoglycolate, regardless of the genotype, possibly
reflecting a metabolic shift towards enhanced regeneration of 3-phosphoglycerate from 2-
phosphoglycolate, at the expense of glyoxylate metabolism, as suggested by the
associated downregulation in 3-oxalomalate levels. Glycolate and glyoxylate metabolism
have been linked to oxidative stress in peroxisomes (Schrader and Fahimi, 2006), essential
organelles mediating biosynthetic and biodegradative reactions in a variety of cells
(Terlecky et al., 2012). 2-phosphoglycolate is produced as a by-product of oxidative DNA
damage (Segerer et al., 2016), and is also toxic for cells as a source of glycolate
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accumulation (Flugel et al., 2017). Conversion of glycolate into glyoxylate, a precursor of
3-oxalomate (Irace et al., 2007), is reduced in rats subjected to oxidative stress (Recalcati
et al., 2003). This may lead to adverse effects as oxalomalate is known to prevent LPS-
induced production of nitric oxide by activated macrophages (Irace et al., 2007).
Peroxisome-associated oxidative stress is a mechanism thought to contribute to
neurotoxicity, inflammation, cognitive dysfunction, and accelerated brain aging (Moruno-
Manchon et al., 2018; Terlecky et al., 2012), but whether the metabolic changes seen in
females reflect a pro- or anti-oxidant status will need to be addressed in further studies.
In PBS-treated mice, metabolic differences were not associated with significant sex
differences in the number of astrocytes and microglia, or microglial soma size, a
morphological activation marker. The area covered by microglia was, however, lower in
the hippocampus of WT females, which could reflect reduced ramification per cell, as
previously reported in females (Young et al., 2018). This reduction was not seen in
APP/PS1 female mice, consistent with recent observations. Microglia of APP/PS1 mice was
indeed found to develop ramifications in the presence of Aβ plaques, regardless of sex, 
but this response occurs earlier in females than in males (Frigerio et al., 2019), which can
be related to the faster progression of cerebral amyloidosis consistently seen in females
from this genotype (Frigerio et al., 2019; Li et al., 2016; Wang et al., 2003). APP/PS1
female mice also slightly differed from WT mice in their hippocampal metabolic profile, as
well as with their reduced body weight and lack of habituation to repeated exposure to the
Y-maze. But, while sex differences in brain metabolism seen in the ageing WT mouse brain
have been hypothesised to contribute to the greater susceptibility of females to AD-like
pathology (Zhao et al., 2016), our data do not support a link between differences in
hippocampal metabolism and early-stage amyloidosis. The implication of the few
metabolites found to be less abundant in the hippocampus of female APP/PS1 mice in Aβ 
plaques deposition is currently unknown. In contrast, global differences in hippocampal
metabolism appeared to be emerging at 4.5 months of age between WT and APP/PS1
males, expected to develop the pathology at a slower rate than female, but in the absence
of behavioural and/or physiological changes. Furthermore, the role of the metabolites
found altered in female APP/PS1 mice in microglial morphology or function is also
unknown, and we did not found any association between metabolite levels and microglial
density and/or activation.
Metabolic effects of LPS independent of sex and disease status.
4.5-month-old WT and APP/PS1 mice, regardless of their sex, exhibited a robust
behavioural suppression 4 hours after inoculation with a low systemic LPS dose of
100ug/kg, without concomitant changes in the number and morphology of glial cells in the
hippocampus. This is consistent with findings in 4-month-old C57BL/6J females (Hart et
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al., 2012), but the discrepancy with our previous data showing enlargement of microglial
soma in WT, but not APP/PS1 males at the same time point (Pardon et al., 2016), could
be due to the exacerbating impact of anaesthesia (Ye et al., 2013), as previously discussed
(Pardon et al., 2016). Indeed, morphological activation of microglia would generally occur
6 hours after systemic administration of higher doses of LPS in the healthy brain (Hoogland
et al., 2015), but within 4 hours in the primed hippocampus (Murray et al., 2011). Thus,
the fact that we did not find differences in microglial number and morphology between
sexes and genotypes is consistent with the lack of microglial response at 4 hours post-
LPS, and published reports showing that changes in microglial phenotypes, occurring with
the progression of amyloidosis in this APP/PS1 model, manifest after the age of 5 months
(Martin et al., 2017). A subset of microglia, however, shows signs of activated morphology
and phenotype prior to that, when clustering around Aβ plaques (Martin et al., 2017; Ruan 
et al., 2009), but our data show that both are rare in 4.5-month-old APP/PS1 mice.
As consistently reported with a range of systemic LPS doses, hippocampal
tryptophan levels rapidly increased in the hippocampus of LPS-treated mice, independently
of sex and disease status. This was associated with elevated levels of degradation products
of both the serotonin and nicotinamide pathways of tryptophan metabolism, suggesting
their co-activation, as seen previously (Guo et al., 2016; O'Connor et al., 2009; Parrott et
al., 2016). A shift in the balance of brain tryptophan metabolism towards the kynurenine
pathway is thought to be a major mediator of pro-inflammatory changes following
systemic inflammation, and to ultimately cause serotonin deficiency (Kim and Jeon, 2018).
Although serotonin levels were not measured here, as this would require the optimisation
of a single LC/MS method specifically designed to address behavioural and structural
differences between tryptophan metabolites and related monoamines (Fuertig et al.,
2016), increased levels of its degradation product 5-HIAA could instead suggest an
increase in serotonin turnover. Several studies have shown that elevated hippocampal 5-
HIAA occurring in the first 24 hours after inoculation with systemic LPS were associated
with stable serotonin levels (Pitychoutis et al., 2009; Sens et al., 2017), suggesting an
increased rate of serotonin synthesis (Brodie et al., 1966). Transient region-specific
increases in the activity of enzymes involved in serotonin synthesis were indeed seen 2
hours after systemic LPS in the frontal cortex and midbrain of rats challenged with the
same 100ug/kg dose, but returning to baseline levels by the 6th hour post-inoculation
(Nolan et al., 2000). In agreement with this, a time course microdialysis study showed
that systemic LPS-induced a gradual increase in extracellular hippocampal tryptophan and
5-HIAA levels over 8 hours, which was associated with a transient increase in serotonin
levels, peaking 3-4 hours after administration (Guo et al., 2016). Interestingly, the
subsequent decline towards baseline serotonin levels was associated with a
downregulation of the serotonin/tryptophan ratio and concomitant upregulation of the
23
kynurenine/tryptophan ratio, indicating a metabolic shift towards kynurenine metabolism
(Guo et al., 2016). Increased 2PY levels, reflecting the amount of nicotinamide
biosynthesized from tryptophan (Shibata and Matsuo, 1990), have been linked to
activation of tryptophan metabolism through the kynurenine pathway and associated with
systemic inflammation in malnutrition (Guerrant et al., 2016; Mayneris-Perxachs et al.,
2016). We can, therefore, hypothesise that the elevated hippocampal 2PY levels we saw
4 hours after LPS administration would reflect an activation of the tryptophan-nicotinamide
pathway, but whether or not its association with elevated hippocampal 5-HIAA levels
predict a metabolic shift towards kynurenine metabolism will need to be determined in
future studies, by measuring the levels of serotonin and key intermediates of the
kynurenine pathway at later points. This is particularly important because activation of the
serotonin pathway of tryptophan metabolism is protective to the brain whereas activation
of the kynurenine pathway leads to detrimental effects, the former being anti-
inflammatory (Dominguez-Soto et al., 2017) and latter pro-inflammatory (Davis and Liu,
2015) and a major driver of LPS-induced sickness (O'Connor et al., 2009). This is also
consistent with our observed association between 2PY levels and the severity of the
behavioural and temperature response to LPS. The time course of changes in tryptophan
metabolic pathways also has implication for our understanding of the mechanisms
underlying the precipitating influence of systemic infection and inflammation in AD. Recent
findings indeed suggest that reduced serotonin neurotransmission contributes to the
development of early cognitive symptoms of AD (Smith et al., 2017), while upregulation
of key components of the kynurenine pathway are associated with Aβ plaques and 
neurofibrillary tangles in the brain of AD patients (Wu et al., 2013).
We also showed, for the first time, that systemic LPS rapidly inhibited the synthesis
and metabolism of methionine in the hippocampus, illustrated by the lowering of both L-
methionine and its downstream metabolites. Regardless of sex, LPS altered methionine
reversible oxidation and salvage. Methionine reversible oxidation, the process whereby
methionine is oxidized into methionine sulfoxide, which is then reduced back to
methionine, is thought to play a key regulatory role in mediating activity-dependent plastic
changes in cellular excitability (Hoshi and Heinemann, 2001). The reduction in the levels
of the methionine oxidation product L-methionine S-oxide by LPS could be seen as a
protective response since reversible methionine oxidation becomes impaired in ageing and
related diseases, leading to the accumulation of toxic methionine oxidation products,
oxidative damage to cells (Stadtman et al., 2005) and Aβ accumulation (Moskovitz et al., 
2016). Methionine sulfoxide reductase, the antioxidant enzyme which reduces methionine
sulfoxide back to methionine, is also known to alleviate LPS-induced inflammation in
microglia (Fan et al., 2015). However, we found here that this was associated with reduced
abundance of L-methionine, suggesting that the lack of L-methionine availability, rather
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than enhanced reversible oxidation, caused the lowering of L-methionine S-oxide levels.
The salvage pathway plays a critical role in maintaining optimal methionine levels as
proven by the ability of 5’-methylthioadenosine to replenish the cellular methionine pool
within 24 hours of methionine deprivation (Shiraki et al., 2014). Reduced levels of both S-
adenosyl-L-methionine and 5’-methylthioadenosine, as we saw here associated with
methionine deficiency 4 hours after LPS administration, are thought to be early events
reflecting the activation of the salvage pathway for the rescue of methionine levels, but
this could only confirmed by looking at later time points (Shiraki et al., 2014). A failure of
this mechanism would lead to detrimental effects, by compromising cell differentiation,
growth and survival (Shiraki et al., 2014) as well as protein synthesis and epigenetic
reactions. The methionine salvage pathway indeed recycles the sulphur of 5’-
methylthioadenosine back into methionine, which is critically needed for protein synthesis
(Kabil et al., 2014). S-adenosyl-L-methionine, whose levels were particularly decreased
by LPS in female mice, is a precursor for this reaction but also a methyl donor for epigenetic
reactions and key regulator of metabolism, proliferation, and apoptosis (Albers, 2009).
Persistent downregulation of the salvage pathway could also be damaging due to the anti-
inflammatory properties of both S-adenosyl-L-methionine and 5’-methylthioadenosine (Ge
et al., 2018; Hevia et al., 2004; Moreno et al., 2006; Pfalzer et al., 2014), whose levels
were also found reduced in the AD brain (Morrison et al., 1996). However, while
methionine deficiency, if persistent, can impair multiple aspects of cell function, and
ultimately cell viability (Shiraki et al., 2014), and as such contribute to the development
of AD, its excess is also neurotoxic leading to inflammation and exacerbation of
behavioural and neurological markers of AD (Tapia-Rojas et al., 2015), perhaps
questioning the functional significance of our findings. Reduced availability and metabolism
of methionine is indeed thought to be the main driver of lifespan and healthspan
enhancement by dietary restriction through improved lipid metabolism as well as reduced
oxidative stress, inflammation and susceptibility to immune and central nervous disorders
(Martinez et al., 2017; Orgeron et al., 2014). Methionine metabolism is indeed reduced in
the long-lived naked-mole rat (Lewis et al., 2018) but it is enhanced in the long-lived
Ames dwarf mouse (Uthus and Brown-Borg, 2003), and both show activation of anti-
inflammatory pathways (Cheng et al., 2017; Dhahbi et al., 2007).
Thus, whether our observed rapid downregulation of methionine metabolism by
LPS constitutes a beneficial or detrimental response in the brain cannot be fully answered
in this study and our data also suggest that this may be, in part, sex-dependent. Indeed,
O-succinyl-L-homoserine contributes to the synthesis of both homocysteine and L-
methionine (Flavin and Slaughter, 1967), and in the present study, it was less abundant
in LPS-treated females. This is particularly relevant to the link between immune responses
and AD progression, since homocysteine can trigger neuroinflammation and microglial
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activation (Chen et al., 2017) and its levels are positively associated with the risk of
dementia (Smith et al., 2018), therefore suggesting a protective downregulation of
methionine metabolism in females. In contrast, in LPS-treated males instead presented
with increased levels of glutathione disulfide, a toxic oxidized form of glutathione and an
end product of methionine metabolism, whose circulating levels were found to be elevated
in inflammatory conditions (Ikegami et al., 1994), and reduced in the long-lived naked-
mole rat (Lewis et al., 2018), suggesting a more damaging downregulation of methionine
metabolism.
Sexual dimorphism in the hippocampal metabolic response to LPS.
Changes in body temperature, pyruvate and methylglyoxal metabolism 4 hours
after onset of systemic inflammation were clearly sex-dependent. Thermoregulatory
responses to LPS in rodents are made of one to three phases of hyperthermia and/or
hypothermia, although fever is less likely to occur in mice than in rats (Blanque et al.,
1996; Romanovsky et al., 2005). LPS-induced hypothermia is seen as a thermoregulatory
"failure", thought to reflect the inability of the brain to regulate body temperature in shock
(Romanovsky et al., 2005). It is also an indicator of the severity of LPS responses, as it
was found to be dose-dependent and more pronounced in mouse strains susceptible to
this endotoxin (Blanque et al., 1996). Consistent with our findings, LPS-induced
hypothermia is generally found to be more severe in male than female mice (Cai et al.,
2016; Card et al., 2006), suggesting that they experience more severe acute effects of
LPS. Hypothermia is thought to be in part induced in response to changes in the brain as
it did not appear to be related to variations in circulating levels of IL-1β, IL-6 or IL-10 
(Blanque et al., 1996; Skelly et al., 2013). Our data showing that LPS-induced
hypothermia is correlated with increased 2PY levels, thought to reflect an activation of the
tryptophan-nicotinamide pathway, are consistent with previous reports showing that
sickness responses to LPS are in part mediated by activation of the kynurenine pathway
(O'Connor et al., 2009) and the ability of kynurenine and its metabolites to potentiate
drug-induced hypothermic responses (Lapin, 2003). Here, hypothermia was sex-
dependent and this was also associated with a reduction in hippocampal pyruvate
metabolism particularly affecting APP/PS1 males. A possible link cannot be ruled out as
hypothermia was found to cause a progressive decrease in cerebral pyruvate contents in
the rat (Nilsson et al., 1975), although central administration of pyruvate did not
significantly alter body temperature (Soto et al., 2018). Pyruvate is an intermediate
energy metabolite of glucose with potent anti-oxidant and anti-inflammatory actions (Das,
2006). Sex differences in pyruvate metabolism have been associated with a higher
mitochondrial respiration rate and reduced oxidative stress in females (Gaignard et al.,
2015), as well as protection against oxidative damage induced by excitotoxic injury
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whereby the ratio of lipid peroxidation markers over pyruvate increased in males but
decreased in females in response to an ischemic insult (Wagner et al., 2004). Evidence of
anti-inflammatory effects of pyruvate in the brain include the demonstration that
treatment with its ethyl pyruvate derivatives exerts robust neuroprotective effects, in both
the post-ischemic brain and LPS-treated animals, by alleviating microglial activation and
neutrophil infiltrations in vivo, and inhibiting LPS-induced pro-inflammatory changes in
these cells in vitro (Lee et al., 2017; Lee et al., 2013). In addition, dietary supplementation
with pyruvate was found to improve spatial memory impairments and brain energy
metabolism in males of the same APP/PS1 mouse line as used here (Koivisto et al., 2016)
as well as in male and female 3xTg-AD mice, while also reducing oxidative stress, albeit
without effects on Aβ and tau pathology (Isopi et al., 2015). Although systemic 
inflammation has been linked to cognitive decline and AD progression in both males and
females (Holmes et al., 2009; Trollor et al., 2010), sex-specific differences were found in
the association between pro-inflammatory mediators and cognitive function in mild
cognitively impaired patients (Trollor et al., 2010). Thus, the present finding that male
APP/PS1 mice were more susceptible to downregulation of pyruvate metabolism in the
early hours post-inoculation with LPS could constitute a male-specific mechanism
underlying exacerbation of cognitive and neurodegenerative changes after systemic
inflammation.
In contrast, females displayed a downregulation of methylglyoxal metabolism
illustrated by reduced levels of its upstream regulators, with the exception of glycolysis,
and of its reduction product D-lactate. Methylglyoxal is a cytotoxic and pro-inflammatory
glycotoxin whose deleterious effects are due to its role as a major precursor of advanced
glycation end-products, and have been associated with several pathologies including
diabetes, ageing and neurodegenerative diseases (Allaman et al., 2015; Angeloni et al.,
2014; Beeri et al., 2011). Cerebrospinal fluid as well as serum methylglyoxal
concentrations are increased in AD patients (Beeri et al., 2011; Kuhla et al., 2005) and
the latter has been found to be associated with cognitive decline regardless of sex (Beeri
et al., 2011). Direct administration of methylglyoxal was also found to cause cognitive
deficits in rats (Hansen et al., 2016) and its accumulation promotes inflammation
(Vulesevic et al., 2016) as well as Aβ aggregation (Woltjer et al., 2003). Methylglyoxal is 
also produced by Aβ, contributing to cell death (Tajes et al., 2014), providing a link 
between inflammation and AD exacerbation. In this context, we can hypothesise that the
inhibition of methylglyoxal metabolism seen in females in response to systemic
inflammation would constitute a protective response that, if persistent, may limit
inflammation-induced exacerbation of AD-like pathology. The mechanism behind a sexual
dimorphism in this response, is however unknown. Females were found to be more
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susceptible to the acute toxicity of methylglyoxal (Peters et al., 1978), but the present
study is the first show a sex-dependent response of this metabolic pathway to immune
stimulation. Nevertheless, methylglyoxal metabolism has been implicated in obesity and
diabetes (Matafome et al., 2013), the risk of which is exacerbated by systemic
inflammation (Esser et al., 2014), and females have been found less susceptible to diet-
induced obesity and its metabolic and pro-inflammatory consequences (Dorfman et al.,
2017). Our finding is, however, consistent with the elevated levels of the anti-
inflammatory cytokine IL-10 that we found in LPS-treated females, but not males, at the
4 hour time point. Indeed, methylglyoxal was found to particularly inhibit the secretion of
IL-10 and TNFα by myeloid cells (Price et al., 2010), whereas IL-10 can suppress pro-
inflammatory and toxic effects of methylglyoxal (Onishi et al., 2015).
5. Conclusions
Taken together, our data indicate that while hippocampal metabolism in females,
compared to males, may reflect a shift towards a pro-inflammatory and pro-oxidant
signature, and while subtle metabolic differences in APP/PS1 mice compared to their WT
littermates were only seen in females, in the early hours following inoculation with LPS,
the physiological and metabolic responses of males are more pronounced, regardless of
the genotype. This is consistent with recent findings in a model of traumatic brain injury,
whereby males exhibited a more aggressive neuroinflammatory profile than female mice
during the acute and subacute phases post-injury (Villapol et al., 2017), and also with the
recently established sexual dimorphism in microglia. The molecular signature of male
microglia was indeed found to be skewed towards pro-inflammatory activation and that of
females found to be neuroprotective, expressing proteins related to the inhibition of
inflammatory responses and promotion of repair mechanisms (Guneykaya et al., 2018;
Villa et al., 2018a; Villa et al., 2018b). Metabolic changes in the hippocampus occurred in
the present study before morphological signs of microglial activation could be detected,
affecting pathways known to modulate microglial activation. This provides insights into
how systemic LPS, whose brain penetration is poor at low dose and in the absence of blood
brain barrier dysfunction (Banks and Robinson, 2010; Varatharaj and Galea, 2017), can
trigger rapid inflammatory responses in the brain. Importantly, we have found here that
some of the metabolic changes are sex-specific, highlighting the importance of taking
gender into consideration when studying susceptibility to inflammatory conditions and AD
exacerbation. Moreover, this study is the first to show an association between onset of
systemic inflammation and downregulation of hippocampal methionine metabolism, but
the protective or detrimental nature of this change needs to be determined in future
studies. No major differences in the response to LPS were seen here between WT and
28
APP/PS1 mice, which can be due to the early pathological stages under investigation, since
differences in microglial activation are subtle before the age of 4 months (Martin et al.,
2017; Ruan et al., 2009), and/or the early time point, as the resolution of
neuroinflammation is an active process particularly impaired in neurodegenerative
diseases (Schwartz and Baruch, 2014). However, some of the metabolic changes that we
saw here in the hippocampus, a brain area critically affected by AD, 4 hours after induction
of systemic inflammation with LPS, are relevant to AD pathogenesis, particularly the
activation of the tryptophan-nicotinamide pathway, reduced methionine availability and
salvage as well as the reduction in pyruvate metabolism in male The extent to which a
single infectious episode is sufficient to drive the progression of AD in susceptible
individuals is not currently known. Looking at the persistence of these metabolic
alterations in relation to the progression of behavioural and neurological hallmarks of AD
may help answering into this question.
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Figure captions.
Figure 1. LPS-induced behavioural suppression at 4 hours post-injection is
independent of sex or genotype. A) Timeline of the experiment. 4.5-month-old male
and female APP/PS1 mice and their wild-type (WT) littermates (n=5-6) were subjected to
baseline assessment of spatial working memory performance and exploratory drive in the
spontaneous test as well as food burrowing behaviour prior to receiving a tail vein
injection of lipopolysaccharide (LPS, 100 μg/kg) or its vehicle (phosphate buffer saline, 
PBS). Induced sickness effects were tested at 4 hours post-injection in the same tests,
prior to blood and tissue collection. At this time point, a significant decrease in core body
temperature was observed in males, regardless of their genotype (B). LPS also suppressed
food burrowing activity (C) and exploratory drive in the spontaneous alternation test,
assessed through the number of arms visits (E), regardless of sex and genotype, but
baseline performance for these behavioural measures did not differ between groups (C,D).
Female mice overall exhibited lower spontaneous alternation performance than their male
counterparts at baseline (F), but LPS had no significant impact on this measure (G).
Parametric data are expressed as Means + SEM. Dots represent individual animals. Post-
hoc tests: * p< 0.05; ** p<0.01, *** p<0.0001 vs PBS or baseline. Food burrowing data
were rank-transformed for statistical analysis but represented as non-normalised
responses and expressed as Median + interquartile range. Sickness scores are represented
as the difference between pre- and post-injection performance. Within-subjects pairwise
comparisons following 3-way ANOVAs: # p<0.05; ## p<0.01, ### p<0.0001 compared to
baseline performance (E).
Figure 2. LPS-induced plasma cytokine at 4 hours post-injection. 4.5-month-old
male and female APP/PS1 mice and their wild-type (WT) littermates were challenged with
LPS (100µ/kg i.v.) or its vehicle PBS. Their plasma was collected 4 hours later, immediately
after behavioural assessment, for measurement of induced levels of pro- and anti-
inflammatory cytokines. At this time point, a significant increase in circulating Interleukin
6 (IL-6, A), which has both pro- and anti-inflammatory effects, was observed regardless
of sex and genotype (A). Levels of the pro-inflammatory cytokine tumour necrosis factor
alpha (TNF-α) were increased by LPS in females, particularly WT females (B), but the 
levels of the other pro-inflammatory mediator, interferon gamma (IFN-γ), were unaltered 
(C). A significant increase in circulating levels of the anti-inflammatory cytokine IL-10, was
also observed in females, regardless of genotype (E). Data were rank-transformed for
statistical analyses but are expressed as Median + interquartile range of non-normalised
responses. Dots represent individual animals. Pairwise comparisons: * p<0.05; **
p<0.01, *** p<0.0001 vs PBS.
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Figure 3. Score plots of Principal Component Analysis (PCA) and two-class
Orthogonal Partial Least Square Discriminant Analysis (OPLS-DA) models for
hippocampal metabolism at 4 hours post-injection with LPS or PBS. R2: variance
explained, Q2: variance predicted. Dots represent individual animals. A). PCA analysis
reveals global metabolic differences between LPS-treated males and females regardless of
genotype [PC1 (X axis): R2X[1] = 0.232, Q2 = 0.115; PC2 (Y axis): R2X[2] = 0.123, Q2 =
0.082). B) Global OPLS-DA model (R2= 0.994, Q2 = 0.886) revealing clear separations
between PBS- and LPS-treated mice (X axis: predictive component), but also some
separation between LPS-treated male and female mice (Y axis: first orthogonal
component), regardless of genotype. C) Accordingly, the class OPLS-DA model comparing
genotypes in PBS-treated mice confirmed the lack of clear separation between WT and
APP/PS1 mice (R2= 0.697, Q2 = 0.244). Predictive component 1 (X axis) vs 2 (Y axis). 2-
class OPLS-DA models confirmed the strong differences in hippocampal metabolism due
to sex in the absence of immune stimulation, (R2= 0.985, Q2 = 0.809; D) as well as the
excellent separation between PBS- and LPS-treated mice males (R2= 1.00, Q2 = 0.857; E)
and females (R2= 1.00, Q2 = 0.863, F). D-F: Predictive (X axis) vs 1st orthogonal (Y axis)
component.
Figure 4. Increased hippocampal tryptophan metabolism 4 hours after systemic
LPS administration. 4.5-month-old male and female APP/PS1 mice and their wild-type
(WT) littermates were challenged with LPS (100µ/kg i.v.) or its vehicle PBS. Schematic
representation of the anti-inflammatory serotonin, and pro-inflammatory kynurenine,
pathways of tryptophan metabolism. At 4 hours post-injection, LPS-treated mice showed
significant upregulation of L-tryptophan (A) as well as of 5-Hydroxylindoleacetic acid (B)
and N1-Methyl-2-pyridone-5-carboxamide (2PY, C), the end metabolites of the serotonin
and kynurenine pathways, respectively. Changes in 2PY levels were negatively correlated
to D) rectal temperature in males (r = -0.718, p = 0.0004) which exhibited an
hypothermic response to LPS but not females 9r = -0.21, p = 0.37); E) the number of
arms visited in the spontaneous alternation test 4 hours after the injection in both males
(r = -0.837, p < 0.0001) and females (r = -0.791, p < 0.0001); and F) sickness scores
for arm visits in both males (r = -0.741, p < 0.0001) and females (r = -0.824,
p < 0.0001), suggesting that increased 2PY levels is associated with the severity of LPS-
induced sickness. Data are expressed as Means + SEM. Dots represent individual animals.
Discriminant metabolites are highlighted by grey text boxes. Pairwise comparisons
following 3-way ANOVAs: *, p<0.05; **, p<0.01; **, p<0.0001 compared to PBS-treated
mice of same sex and genotype.
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Figure 5. Reduced hippocampal methionine metabolism 4 hours after systemic
LPS administration. 4.5-month-old male and female APP/PS1 mice and their wild-type
(WT) littermates were challenged with LPS (100µ/kg i.v.) or its vehicle PBS. Schematic
representation of methionine metabolism showing downregulation of 4 key metabolites of
this pathway in LPS-treated mice, at 4 hours post-injection, regardless of sex or genotype
(A-D). Two of these metabolites, L-methionine-S-Oxide (B) and 5’-Methylthioadenosine
(D), as well as 2 methionine derivatives involved in taurine metabolism, L-Cystathionine
(E) and hypotaurine (F), were also found in significantly reduced levels in females
compared to males. Data are expressed as Means + SEM. Dots represent individual
animals. Discriminant metabolites are highlighted by grey text boxes. Pairwise
comparisons following 3-way ANOVAs: *, p<0.05; **, p<0.01; **, p<0.0001 compared
to PBS-treated mice of same sex and genotype; ++, p<0.01, +++, p<0.0001 compared to
males. #, p<0.05; ##, p<0.01; ###, p<0.0001; compared to PBS-treated males of same
genotype.
Figure 6. Reduced pyruvate metabolism in the hippocampus of APP/PS1 male 4
hours after systemic LPS administration. 4.5-month-old male and female APP/PS1
mice and their wild-type (WT) littermates were challenged with LPS (100µ/kg i.v.) or its
vehicle PBS. Schematic representation of the pyruvate metabolic pathway and its links
with the sorbitol and glycolate pathways. At 4 hours post-injection, LPS-treated APP/PS1
male mice failed to show a reduction in D-sorbitol levels (A), but in contrast, exhibited
downregulation of 4 key metabolites of the pyruvate metabolic pathway: 3-Phospho-D-
glycerate (B), 2-phosphoglycolate (C), phosphoenolpyruvate (D) and pyruvate (E). Data
are expressed as Means + SEM. Dots represent individual animals. Discriminant
metabolites are highlighted by grey text boxes. Pairwise comparisons following 3-way
ANOVAs: *, p<0.05; **, p<0.01; compared to PBS-treated mice of same sex and
genotype. #, p<0.05; ##, p<0.01; ###, p<0.0001; compared to PBS-treated males of same
genotype.
Figure 7. Reduced methylglyoxal metabolism in the hippocampus of WT and
APP/PS1 female 4 hours after systemic LPS administration. 4.5-month-old male
and female APP/PS1 mice and their wild-type (WT) littermates were challenged with LPS
(100µ/kg i.v.) or its vehicle PBS. Schematic representation of the main pathways
regulating methylglyoxal metabolism. At 4 hours post-injection, LPS-treated APP/PS1
female mice showed a reduction in lipid metabolism, with downregulation of 5 key
metabolites involved in fatty acid and glycerolipid metabolism: hexadecanoic acid (A),
octadecanoic acid (B), Icosatrienoic acid (C) and [FA (17:0)] heptadecanoic acid (D) and
sn-Glycerol 3-phosphate (E). This was associated with reduced levels of (D)-S-
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Lactoylglutathione (F) and (D)-Lactate (G), the reduction products of methylglyoxal. Data
are expressed as Means + SEM. Dots represent individual animals. Discriminant
metabolites are highlighted by grey text boxes. Pairwise comparisons following 3-way
ANOVAs: *, p<0.05; **, p<0.01; ***, p<0.0001 compared to PBS-treated mice of same
sex and genotype. #, p<0.05; compared to PBS-treated males of same genotype.
Figure 8. Lack of microglial response to LPS in the hippocampus at 4 hours post-
injection. 4.5-month-old male and female APP/PS1 mice and their wild-type (WT)
littermates were challenged with LPS (100µ/kg i.v.) or its vehicle PBS. Their brain were
collected 4 hours later, immediately after behavioural assessment, and one hemisphere
was processed for immunostaining of Iba1 positive microglia. Representative images of
Iba1 immunostaining in the whole hippocampus (A), CA1 (B), CA2 (C), CA3 (D), and
dentate gyrus (DG, E) subfields extracted and analysed using a Matlab tool. LPS had no
significant effects on microglial density in any hippocampal areas, estimated through the
quantification the percentage area covered by Iba1 positive microglia (F-J) and number of
microglial cells per mm2 (K-O). The area covered by microglia, was, however, significantly
lower in the hippocampus of WT females (F), particularly in the CA2 (H) and CA3 (G)
subfields, but lower microglial numbers were only observed in the dentate gyrus (O). Data
are expressed as Means + SEM. Dots represent individual animals. Pairwise comparisons:
* p<0.05; ** p<0.01.
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Table 1. Metabolites differently expressed between males and females and in response to LPS. Statistical significance from 3-way ANOVAs
followed by pairwise comparisons testing the effect of LPS within each sex, when appropriate. When significant Genotype, Sex and or their interaction with
treatment were observed, metabolites with VIP values below 1.5 were considered discriminant if pairwise comparisons confirmed genotype or sex
differences in PBS-treated mice and/or a sexually dimorphic LPS response.
Genotype effect
(PBS-treated)
Sex effect
(PBS-treated)
Overall
LPS effect
LPS effect
in males
LPS effect
in females
Exact
mass
RT
(min)
Putative metabolite
Formula Pathway VIP p
vs.
WT VIP p
vs.
males VIP p
vs.
PBS VIP p
vs.
PBS VIP p
vs.
PBS
Amino acid metabolism
131.09 11.79
(3R)-beta-Leucine
C6H13NO2
Valine, leucine and isoleucine
degradation 1.37 2.04 <0.0001  0.75 0.39 0.64
103.10 15.33
Choline
C5H13NO
Glycine, serine and threonine
metabolism 0.83 0.71 1.45 2.00 <0.0001  0.69
222.07 11.11
L-cystathionine
C7H14N2O4S
Glycine, serine and threonine
metabolism
Methionine metabolism
1.35 1.39 0.01  0.89 0.65 0.88
149.05 8.79
L-methionine
C5H11NO2S
Methionine metabolism 0.69 0.57 2.92 <0.0001  2.14 <0.0001  1.88 <0.0001 
165.05 9.32
L-methionine S-oxide
C5H11NO3S
Methionine metabolism 0.69 0.83 2.52 <0.0001  1.84 <0.0001  1.77 <0.0001 
384.12 9.50
S-adenosyl-L-homocysteine
C14H20N6O5S
Methionine metabolism 0.92 1.18 0.91 1.70 0.0001  1.10 0.036 
219.07 9.59
O-succinyl-L-homoserine
C14H20N6O5S
Methionine metabolism 0.72 1.18 2.04 <0.0001  1.31 0.03  1.50 <0.0001 
398.14 11.02
S-adenosyl-L-methionine
C15H22N6O5S
Methionine metabolism
Arginine and proline
metabolism
1.13 0.70 1.82 0.0002  1.30 1.37 0.0002 
297.09 6.79
5'-methylthioadenosine
C11H15N5O3S
Methionine metabolism
Arginine and proline
metabolism
1.31 1.57 0.0001  2.44 <0.0001  2.00 <0.0001  1.70 <0.0001 
132.05 8.62
N-carbamoylsarcosine
C4H8N2O3
Arginine and proline
metabolism 0.92 1.07 1.84 0.0002  1.37 0.004  1.21 0.005 
231.07 8.97
N-succinyl-L-glutamate 5-
semialdehyde
C9H13NO6
Arginine and proline
metabolism 1.25 1.75 0.0005  0.72 1.34 0.009  1.37 0.005 
104.02 9.07
Urea-1-carboxylate
C2H4N2O3
Arginine and proline
metabolism 1.20 0.60 1.87 <0.0001  1.80 <0.0001  1.07 0.03
 in
WT
188.13 16.71
Homoarginine
C7H16N4O2
Arginine and proline
metabolism 1.17 1.88 <0.0001  1.06 0.63 1.38
133.04 10.25
L-aspartate
C4H7NO4
Arginine and proline
metabolism
Lysine biosynthesis
1.00 1.39 1.02 1.78 0.004  0.97
276.13 10.24
N6-(L-1,3-Dicarboxypropyl)-
L-lysine
C11H20N2O6
Lysine biosynthesis 1.16 1.52 0.002  0.72 0.32 0.93
203.08 9.24
N2-acetyl-L-aminoadipate
C8H13NO5
Lysine biosynthesis 1.31 1.75 0.001  0.90 0.75 1.14
161.07 10.10
L-2-aminoadipate
C6H11NO4
Lysine biosynthesis 1.44 1.69 0.008  0.80 1.06 0.78
129.08 9.34
L-pipecolate
C6H11NO2
Lysine degradation
Alkaloid biosynthesis I
1.38 1.65 <0.0001  0.91 0.86 0.79
151.06 5.15
(Z)-4-
hydroxyphenylacetaldehyde-
oxime
C8H9NO2
Tyrosine metabolism 1.28 1.85 <0.0001  0.82 0.97 0.57
190.05 8.17
[FA hydroxy,oxo(7:0/2:0)] 4-
hydroxy-2-oxo-Heptanedioic
acid
C7H10O6
Tyrosine metabolism 1.12 1.59 0.003  0.91 1.30 0.03  1.51 0.0002 
165.08 8.00
L-phenylalanine
C9H11NO2
Phenylalanine, tyrosine and
tryptophan biosynthesis 0.83 0.78 2.19 <0.0001  1.87 <0.0001  1.44 0.003
in
WT
204.09 9.16
L-tryptophan
C11H12N2O2
Phenylalanine, tyrosine and
tryptophan biosynthesis
Tryptophan metabolism
1.47 1.64 0.09 2.55 <0.0001  1.94 <0.0001  1.67 <0.0001 
191.06 9.66
5-hydroxyindoleacetate
C10H9NO3
Tryptophan metabolism 1.07 0.84 2.32 <0.0001  2.04 <0.0001  1.31 0.0012 
219.11 6.80
Pantothenate
C9H17NO5
beta-Alanine metabolism
Pantothenate and CoA
biosynthesis
1.27 2.06 0.0001  0.75 0.93 1.16
160.08 6.83
D-alanyl-D-alanine
C6H12N2O3
D-Alanine metabolism
Peptidoglycan biosynthesis
1.35 0.03  2.08 <0.0001  0.99 0.98 0.72
612.15 11.03
Glutathione disulfide
C20H32N6O12S2
Glutamate metabolism
Glutathione metabolism
0.82 1.37 0.77 1.51 0.001  1.10
140.06 7.25
Methylimidazoleacetic acid
C6H8N2O2
Histidine metabolism 0.97 1.40 0.88 1.51 0.002  1.01
169.08 9.39 N(pi)-methyl-L-histidine Histidine metabolism 1.32 2.00 <0.0001  1.62 <0.0001  1.70 <0.0001  1.59 0.0005 
C7H11N3O2
109.02 10.64
Hypotaurine
C2H7NO2S
Taurine and hypotaurine
metabolism 1.43 2.07 <0.0001  0.95 0.87 0.95
Carbohydrate metabolism
118.03 10.42
Succinate
C4H6O4
Citrate cycle (TCA cycle)
Glyoxylate and dicarboxylate
metabolism
1.14 0.65 1.69 0.0003  1.40 0.005  1.18 0.01 
192.03 8.66
Isocitrate
C6H8O7
Citrate cycle (TCA cycle)
Glyoxylate and dicarboxylate
metabolism
1.34 1.91 <0.0001  0.96 1.02 0.82
134.02 10.92
(S)-malate
C4H6O5
Citrate cycle (TCA cycle)
Pyruvate metabolism
Glyoxylate and dicarboxylate
metabolism
0.97 0.82 1.46 0.79 1.53 0.0001 
90.03 7.25
(D)-lactate
C3H6O3
Pyruvate metabolism 0.90 0.95 1.88 1.08 1.55 <0.0001 
379.10 9.05
(D)-S-lactoylglutathione
C13H21N3O8S
Pyruvate metabolism 0.90 0.93 1.26 0.53 1.63 0.0008 
167.98 11.75
Phosphoenolpyruvate
C3H5O6P
Citrate cycle (TCA cycle)
Pyruvate metabolism
Glycolysis / Gluconeogenesis
1.08 1.48 <0.0001  1.23 1.79 0.01  0.78
88.01 6.81
Pyruvate
C3H4O3
Citrate cycle (TCA cycle)
Glycolysis / Gluconeogenesis
0.73 0.16 0.70 1.66 0.03  0.53
170.00 10.31
D-glyceraldehyde 3-
phosphate
C3H7O6P
Glycolysis / Gluconeogenesis 0.87 0.33 1.70 0.0007  1.10 0.04
 in
APP/
PS1
1.28 0.003
 in
APP/
PS1
185.99 11.39
3-phospho-D-glycerate
C3H7O7P
Glycolysis /Gluconeogenesis
Glyoxylate and dicarboxylate
metabolism
0.99 1.35 <0.0001  1.10 1.69 0.007  0.67
155.98 11.41
2-phosphoglycolate
C2H5O6P
Glyoxolate and dicatboxylate
metabolism 1.28 2.11 <0.0001  1.08 1.54 0.0007  0.71
206.01 11.83
3-oxalomalate
C6H6O8
Glyoxolate and dicatboxylate
metabolism 1.28 2.00 <0.0001  0.85 0.91 0.61
164.07 9.24
L-rhamnose
C6H12O5
Fructose and mannose
metabolism 0.99 0.78 1.16 1.51 0.002  0.85
182.08 10.09
D-sorbitol
C6H14O6
Fructose and mannose
metabolism 1.07 0.96 2.06 <0.0001  1.40 0.002
 in
WT 1.65 <0.0001 
276.02 11.62
6-phospho-D-gluconate
C6H13O10P
Pentose phosphate pathway 0.79 0.86 1.70 0.0006  1.07 0.08 1.33 0.001 
154.00 8.48
Propanoyl phosphate
C6H13O10P
Propanoate metabolism
C5-Branched dibasic acid
metabolism
1.05 0.85 0.98 1.53 0.0009  0.64
130.03 8.65
Itaconate
C5H6O4
C5-Branched dibasic acid
metabolism
Citrate cycle (TCA cycle)
1.34 1.91 <0.0001  0.94 1.10 0.74
146.02 9.93
Methyloxaloacetate
C5H6O5
C5-Branched dibasic acid
metabolism 1.20 1.53 0.006  0.95 0.88 0.94
Nucleotide metabolism
136.04 8.58
Hypoxanthine
C5H4N4O
Purine metabolism 0.77 0.78 1.00 1.66 0.03  0.94
168.03 9.07
Urate
C5H4N4O3
Purine metabolism 0.22 0.59 2.17 <0.0001  1.77 <0.0001  1.34 0.006 
463.07 11.88
N6-(1,2-Dicarboxyethyl)-AMP
C14H18N5O11P
Purine metabolism 0.85 0.71 1.52 0.69 1.52 <0.0001 
156.02 7.91
Orotate
C5H4N2O4
Pyrimidine metabolism 1.21 1.58 0.005  0.83 1.08 1.18 0.01 
242.09 6.82
Thymidine
C10H14N2O5
Pyrimidine metabolism 0.57 0.26 2.05 <0.0001  1.88 0.002  1.18 0.0007 
126.04 6.82
Thymine
C5H6N2O2
Pyrimidine metabolism 0.74 0.98 1.87 <0.0001  1.77 0.002  1.03 0.005 
114.04 7.17
5,6-dihydrouracil
C4H6N2O2
Pyrimidine metabolism
Beta-Alanine metabolism
Pantothenate and CoA
biosynthesis
0.70 0.88 0.77 1.52 0.0007  0.93
Lipid metabolism and Fatty acyls
284.27 3.88
Octadecanoic acid
C18H36O2
Fatty acids biosynthesis
Biosynthesis of unsaturated
fatty acids
1.13 0.99 1.50 0.004  inWT 0.89 1.46 0.005 
256.24 3.91
Hexadecanoic acid
C16H32O2
Biosynthesis of unsaturated
fatty acids 1.21 1.18 1.52 0.002  0.92 1.35 0.01 
306.25 3.88
Icosatrienoic acid
C20H34O2
Biosynthesis of unsaturated
fatty acids 0.70 094 0.88 0.57 1.41 0.001 
304.24 3.88
[FA (20:4)] 5Z,8Z,11Z,14Z-
eicosatetraenoic acid
C20H32O2
Fatty Acids and Conjugates 0.96 0.85 1.32 0.42 1.62 <0.0001 
118.06 5.16
Formyl 3-hydroxy-butanoate
C5H10O3
Fatty esters 1.44 2.17 <0.0001  0.97 1.16 0.88
172.01 10.13
sn-glycerol 3-phosphate
C3H9O6P
Glycerolipid metabolism
Glycerophospholipid
metabolism
0.99 1.34 0.98 0.76 1.33 0.0009 
306.26 3.88
sn-glycero-3-
Phosphoethanolamine
C5H14NO6P
Glycerophospholipid
metabolism
Ether lipid metabolism
1.26 1.37 1.79 0.47 1.69 <0.0001 
393.29 4.82
PGH2-EA
C23H39NO4
Eicosanoids 1.11 1.05 1.73 0.0003  1.40 0.01  1.18 0.005 
Energy Metabolism
506.99 10.98
ATP
C10H16N5O13P3
Oxidative phosphorylation
Purine metabolism
1.04 0.80 1.97 <0.0001  1.47 0.002  1.28 0.0004 
340.00 11.91
D-fructose 1,6-bisphosphate
C6H14O12P2
Carbon fixation 1.04 1.54 0.002  1.44 0.0005  1.15 0.05  1.21 0.003 
370.01 12.01
D-sedoheptulose 1,7-
bisphosphate
C7H16O13P2
Carbon fixation 1.23 1.22 1.32 0.81 1.52 <0.0001 
Metabolism of Cofactors and Vitamins
73.02 10.25
Iminoglycine
C2H3NO2
Thiamine metabolism 0.71 0.98 1.00 1.56 0.001  0.91
152.06 6.87 N1-methyl-2-pyridone-5-carboxamide
C7H8N2O2
Nicotinate and nicotinamide
metabolism 0.81 0.61 2.73 <0.0001  2.25 <0.0001  1.62 <0.0001 
Peptides
276.10 11.03
Gamma glutamylglutamic
acid
C10H16N2O7
Peptide 0.95 0.94 0.89 1.59 0.005  0.90
262.08 9.71
L-beta-aspartyl-L-
glutamicacid
C9H14N2O7
Peptide 1.52 0.03 in ♀ 0.82 0.65 0.56 0.58
357.13 7.80
Asp-Ser-His
C13H19N5O7
Basic peptide 0.71 0.74 1.54 0.005  0.82 1.36 0.002 
508.18 6.81
Asn-Met-Met-Asn
C18H32N6O7S2
Hydrophobic peptide 0.52 1.01 1.60 1.57 0.003  0.95
482.20 8.23
Asp-Phe-Thr-Thr
C21H30N4O9
Hydrophobic peptide 1.34 0.03 in ♂ 1.59 0.003  0.86 0.69 0.64
360.14 8.79 Asn-Asn-Asn Polar peptide 0.72 0.15 2.87 <0.0001  2.10 <0.0001  1.85 <0.0001 
C12H20N6O7
Biosynthesis of Polyketides and nonribosomal Peptides
509.33 4.64
Narbomycin
C28H47NO7
Biosynthesis of 12-, 14- and
16-membered macrolides 0.61 0.29 2.14 <0.0001  1.44 0.003  1.50 <0.0001 
515.18 11.20
13-dihydrocarminomycin
C26H29NO10
Biosynthesis of type II
polyketide products 1.21 1.71 0.004  0.84 0.86 0.69
Biosynthesis of Secondary metabolites
200.08 7.89
Dihydroclavaminic acid
C8H12N2O4
Clavulanic acid biosynthesis 1.27 2.04 <0.0001  0.80 0.79 0.83
Not known
102.08 16.19
γ-aminobutyramide 
C4H10N2O
Not known 1.23 1.73 0.004  0.77 1.48 0.003  1.37 0.006 
274.05 10.27
1-deoxy-D-altro-heptulose 7-
phosphate
C7H15O9P
Not known 1.13 1.19 1.24 1.65 0.01  0.58
281.11 10.68
1-methyladenosine
C11H15N5O4
Not known 1.54 0.03 in ♀ 0.61 0.1 0.79 0.53
367.27 4.95
3, 5-tetradecadiencarnitine
C21H37NO4
Not known 1.06 1.24 1.57 0.002  1.15 0.01  1.44 0.04 
181.99 9.73
3-
methylphosphoenolpyruvate
C4H7O6P
Not known 1.20 1.77 <0.0001  0.88 0.75 0.83
181.10 8.58
6-methyltetrahydropterin
C7H11N5O
Not known 1.00 1.11 0.83 1.79 0.0006  1.05 0.02 
430.20 5.36
Athamantin
C24H30O7
Not known 1.31 1.79 0.01  0.85 0.78 0.65
348.11 9.24
Camptothecin
C20H16N2O4
Not known 0.97 0.72 1.59 0.02  1.37 0.009  inWT 1.11
158.06 4.39
Dimethyl citraconate
C7H10O4
Not known 0.97 1.72 0.0005  0.53 0.92 1.11
159.13 9.46
DL-2-sulfoctanoicacid
C8H17NO2
Not known 1.09 1.67 0.0002  0.60 0.41 0.88
425.35 4.65
Elaidiccarnitine
C25H47NO4
Not known 1.20 1.44 1.53 0.004  1.19 0.04
in
APP/
PS1
1.14 0.03 inWT
275.14 8.59 Glutarylcarnitine Not known 1.36 1.89 0.007  0.68 0.70 0.87
C12H21NO6
246.05 8.65
Glycerophosphoglycerol
C6H15O8P
Not known 1.28 1.52 0.003  1.29 0.68 1.49 0.0001 
423.33 4.68
Linoelaidylcarnitine
C25H45NO4
Not known 1.28 1.42 1.52 0.003  1.24 0.02  0.98 0.04 
216.12 10.34
N-acetyl-(L)-arginine
C8H16N4O3
Not known 1.15 0.03 in ♀ 1.53 0.005  0.87 0.76 1.28 0.0008 
202.14 14.08
NG,NG-dimethyl-L-arginine
C8H18N4O2
Not known 1.22 0.97 1.32 1.60 0.001  0.81
243.09 8.89
Nocardicin C
C23H26N4O8
Not known 0.91 0.71 1.65 0.71 1.53 <0.0001 
175.03 5.16
Nonulose 9-phosphate
C9H19O12P
Not known 1.15 1.48 0.004  1.81 1.91 <0.0001  0.70
249.03 12.35
Norepinephrinesulfate
C8H11NO6S
Not known 0.97 1.87 0.003  0.75 1.35 0.008  0.72
288.06 8.85
Orotidine
C10H12N2O8
Not known 1.29 1.56 0.0003  0.92 0.59 1.19 0.007 
371.30 4.84
Tetradecanoylcarnitine
C21H41NO4
Not known 1.22 1.53 0.04  1.00 0.90 0.77
573.09 8.83
GDP-3,6-dideoxy-D-galactose
C16H25N5O14P2
Not known 1.17 0.81 1.10 1.79 0.002  0.63
133.07 6.76
N-hydroxyvaline
C5H11NO3
Linamarin biosynthesis 1.29 1.70 <0.0001  2.45 <0.0001  2.14 <0.0001  1.61 <0.0001 
PBS: Phosphate-buffered saline; WT: wild-type; ♀: female; ♂: male.
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Supplementary Figure 1. Body mass (A) was recorded prior to and 4 hours after the PBS or LPS
challenge. The two-way ANOVA with repeated measures revealed a significant Genotype x Sex
interaction effect (F(1,36) = 12.22, p=0.0013). Females were overall lighter than males regardless of
genotype (F(1,36) = 152.67, p<0.0001) but within females, the APP/PS1 mice were also lighter than
their WT littermates (p<0.0001). None of the experimental groups showed significant weight loss at 4
hours following the LPS or PBS challenge. Before injection with PBS or LPS, none of the groups differed
for the number of arm visits in the Y-maze (B), but females showed an overall reduction in spatial
alternation performance (B; Sex effect: F(1,35) = 4.65, p=0.04). At 4 hours post injection, LPS-treated
mice visited significantly less arms of the Y-maze than PBS-treated mice (F(1,36) = 65.53, p<0.0001)
and but PBS-treated APP/PS1 mice were also hyperactive compared to PBS-treated APP/PS1 males and
WT females (p=0.009 in both cases, C), but their spontaneous alternation performance (D) did not
differ. Data are expressed as Means + SEM. *, p<0.05; **, p<0.01; **, p<.0001
C)
***
**
**
**
*
*
**
***
B)
D) E)
Supplementary table 1. Results of the two-way repeated measure ANOVAs on behavioral
measures.
Body weight Food
Burrowing*
Arm entries Alternation rate
Covariate (arm entries) F(1,31)=0.80
p=0.38
Genotype F(1,36)=14.4
p=0.0006
F(1,36)=0.03
p=0.86
F(1,36)=2.12
p=0.15
F(1,36)=0.88
p=0.36
Sex F(1,36)=152.67
p<0.0001
F(1,36)=2.30
p=0.14
F(1,36)=3.17
p=0.08
F(1,36)=0.11
p=0.74
Treatment F(1,36)=2.30
p=0.14
F(1,36)=22.2
p<0.0001
F(1,36)=20.66
p<0.0001
F(1,36)=0.41
p=0.53
Time F(1,35)=9.37
p=0.004
F(1,36)=15.92
p=0.003
F(1,36)=145.25
p<0.0001
F(1,31)=0.18
p=0.68
Genotype X Sex F(1,36)=12.22
p=0.0013
F(1,36)=1.22
p=0.28
F(1,36)=0.59
p=0.45
F(1,36)=1.09
p=0.30
Genotype X Treatment F(1,36)=0.19
p=0.67
F(1,36)=0.20
p=0.66
F(1,36)=0.97
p=0.33
F(1,36)=0.85
p=0.36
Genotype X Time F(1,35)=0.35
p=0.56
F(1,36)=1.62
p=0.21
F(1,36)=3.09
p=0.09
F(1,31)=2.98
p=0.09
Sex X Treatment F(1,36)=0.17
p=0.68
F(1,36)=0.37
p=0.55
F(1,36)=0.28
p=0.60
F(1,36)=0.18
p=0.67
Sex X Time F(1,35)=1.06
p=0.31
F(1,36)=0.06
p=0.81
F(1,36)=0.25
p=0.62
F(1,31)=4.25
p=0.048
Treatment X Time F(1,35)=1.02
p=0.32
F(1,36)=9.47
p=0.004
F(1,36)=58.55
p<0.0001
F(1,31)=0.65
p=0.43
Genotype X Sex X
Treatment
F(1,36)=0.04
p=0.84
F(1,36)=3.13
p=0.08
F(1,36)=0.04
p=0.84
F(1,36)=0.97
p=0.33
Genotype X Sex X Time F(1,35)=0.32
p=0.57
F(1,36)=0.46
p=0.50
F(1,36)=1.20
p=0.28
F(1,30)=0.73
p=0.40
Genotype X Treatment
X Time
F(1,35)=1.05
p=0.31
F(1,36)=0.12
p=0.73
F(1,36)=0.24
p=0.63
F(1,30)=0.01
p=0.91
Sex X Treatment X
Time
F(1,35)=1.29
p=0.27
F(1,36)=0.30
p=0.59
F(1,36)=3.79
p=0.06
F(1,30)=0.00
p=0.95
Genotype X Sex X
Treatment X Time
F(1,35)=0.59
p=0.45
F(1,36)=0.09
p=0.77
F(1,36)=1.94
p=0.17
F(1,30)=0.78
p=0.38
*: Food burrowing data were rank-transformed prior to statistical analyses.
Supplementary table 2. Results of the two-way repeated measure ANOVAs on plasma
cytokine levels. Data were rank-transformed prior to statistical analyses.
IL-6 TNF-α INF-γ IL-1β IL-10
Genotype F(1,30)=0.43
p=0.51
F(1,30)=0.21
p=0.65
F(1,30)=0.59
p=0.45
F(1,30)=0.05
p=0.83
F(1,30)=0.88
p=0.35
Sex F(1,30)=0.76
p=0.39
F(1,30)=1.04
p=0.31
F(1,30)=0.41
p=0.52
F(1,30)=0.93
p=0.34
F(1,30)=5.07
p=0.03
Treatment F(1,30)=116.02
p<0.0001
F(1,30)=7.82
p=0.0089
F(1,30)=2.7
p=0.11
F(1,30)=0.17
p=0.68
F(1,30)=23.49
p<0.0001
Genotype X Sex F(1,30)=0.03
p=0.87
F(1,30)=0.09
p=0.77
F(1,30)=0.37
p=0.55
F(1,30)=0.90
p=0.35
F(1,30)=0.00
p=0.95
Genotype X
Treatment
F(1,30)=4.01
p=0.054
F(1,30)=0.48
p=0.49
F(1,30)=1.12
p=0.30
F(1,30)=0.40
p=0.53
F(1,30)=0.18
p=0.67
Sex X Treatment F(1,30)=3.13
p=0.09
F(1,30)=2.15
p=0.15
F(1,30)=0.98
p=0.33
F(1,30)=0.77
p=0.38
F(1,30)=4.54
p=0.04
Genotype X Sex X
Treatment
F(1,30)=3.00
p=0.09
F(1,30)=2.69
p=0.11
F(1,30)=0.90
p=0.35
F(1,30)=2.26
p=0.14
F(1,30)=1.68
p=0.20
Supplementary metabolomics results
Lack of major metabolic perturbations in the hippocampus of 4.5-month-old APP/PS1 mice
5 of the 98 selected metabolites were found to significantly discriminate between PBS-treated WT
and APP/PS1 mice (Table1), albeit predominantly in females. Levels of L-beta-aspartyl-L-glutamic acid,
which belongs to the family of N-acyl-alpha amino acids and derivatives which are known for their anti-
inflammatory action (1), were particularly reduced in female APP/PS1 mice (Suppl. Fig. 2A), but its function
and implication in AD pathology is, to the best of our knowledge, unknown. 1-Methyladenosine, an oxidized
nucleoside known to be immunosuppressive on macrophage function (2) and found in elevated levels in
the urine of patients with mild-to-moderate AD (3), was more abundant in the hippocampus of female
APP/PS1 mice compared to their WT female littermates (Suppl. Fig. 2B).
Significant Genotype X Treatment interactions were also found for N-acetyl-(L)-arginine
(F(1,34)=12.07, p=0.001), whose levels were significantly lower in PBS-treated APP/PS1 females compared
to PBS-treated WT females (Suppl. Fig. 2C), and for the hydrophobic tetrapeptide Asp-Phe-Thr-Thr
(F(1,34)=5.40, p=0.03), whose levels were significantly increased in PBS-treated APP/PS1 males compared
to their PBS-treated counterparts (Suppl. Fig. 2D). Their function and potential roles in AD pathology are
also, to the best of our knowledge, unknown.
Sex differences in the hippocampal metabolic profile are independent of the APP/PS1 genotype.
Forty-one metabolites with sex differences were identified revealing major changes in amino acids,
carbohydrate metabolism and fatty acyls (Table 1). A few metabolites from other chemical classes and
many unknown metabolites were also found in different levels between PBS-treated males and females
(Table 1). Metabolic differences in the methionine and pyruvate metabolic pathways are described in the
main manuscript and illustrated Fig. 5 and 6, respectively. Changes in other metabolites with previously
associated with differences immune function are described below. Their potential role in brain function or
implication in AD progression is presented in Suppl. Table 3.
These included reduced levels of (3R)-beta leucine (Suppl. Fig. 3), a degradation product of the
anti-inflammatory amino acid L-Leucine (4), D-alanyl-D-alanine (Suppl. Fig. 3B), an anti-inflammatory
antibiotic-binding protein (5), and N(pi)-methyl-L-histidine (Suppl. Fig. 3C), a metabolic product of the
amino acid histidine known to be negatively associated with inflammation in obese women (6). Females
also presented with an increased abundance of N-Succinyl-L-glutamate 5-semialdehyde (Suppl. Fig. 3D),
a metabolite found to be elevated in the plasma of lung cancer patients harbouring a mutation in the
epidermal growth factor receptor (7) that also exacerbate their pro-inflammatory status (8).
Lysine, whose dietary restriction was found to trigger pro-inflammatory changes (9), indicated the
major anti-inflammatory pathway upregulated in females as seen by elevated levels in three metabolites
involved in lysine biosynthesis :N6-(L-1,3-Dicarboxypropyl)-L-lysine, N2-Acetyl-L-aminoadipate and L-2-
Aminoadipate (Suppl. Fig. 3E-G), and reduced levels of L-pipecolate (Suppl. Fig. 3H), a degradation
product of L-lysine whose urine levels are positively associated with low grade inflammation (10).
Differences in amino acid metabolism also indicative of anti-inflammatory effects in females included
increased abundance of pantothenate (vitamin B5; Suppl. Fig. 3I), whose dietary intake was found to
alleviate chronic low grade inflammation (11) and norepinephrinesulfate (Suppl. Fig. 3O), a metabolite of
the anti-inflammatory neurotransmitter norepinephrine (12), as well as reduced levels of (Z)-4-
Hydroxyphenylacetaldehyde-oxime (Suppl. Fig. 3J), an enzyme involved in tyrosine metabolism found in
increased levels in inflammatory bowel disease (13), and homoarginine (Suppl. Fig. 3K), known to be
negatively associated with pro-inflammatory changes (14).
Changes in carbohydrate metabolism and fatty acyls seen in females were indicative of a pro-
inflammatory status. Furthermore, isocitrate, a substrate of the tricarboxylic acid (TCA) cycle found to
exert anti-inflammatory effects in a rat model of mild anemia of inflammation (15) and itaconate, a potent
anti-inflammatory TCA derivative found in immune cells (16), were also less abundant in the female
hippocampus (Suppl. Fig. 3M&N, respectively). Hippocampal concentrations of formyl 3-hydroxy-
butanoate, a fatty ester, were also significantly lower in females (Suppl. Fig. 3L) and fatty esters are
thought to be anti-inflammatory (17).
Metabolites differentially expressed in PBS- and LPS-treated mice regardless of sex and
genotype.
Thirty six metabolites were altered to similar extents by LPS in all experimental groups (Table 1).
The most significant changes were those affecting tryptophan and methionine metabolism, as described in
the main manuscript and represented Figs. 4&5, respectively. Changes to other metabolites associated
with immune status are described below and represented Suppl. Fig. 4, and the potential association of
these metabolites in brain function, sex differences and/or AD progression is described in Suppl. Table 3.
These metabolic differences included increased levels of thymidine and thymine (Suppl. Fig. 4A&B),
two derivatives of the anti-inflammatory nucleotide pyrimidine (18) as well as reduced levels of the
inflammation signalling molecule adenosine triphosphate (ATP) (19), particularly in WT mice (Suppl. Fig.
4C) and of succinate (Suppl. Fig. 4D), a pro-inflammatory intermediate of the TCA cycle which plays a
crucial role in ATP generation (20).
Pro-inflammatory metabolic changes included increased levels of N(pi)-methyl-L-histidine (Suppl.
Fig. 4C), an histidine derivative positively associated with levels of pro-inflammatory markers (21), urate
(Suppl. Fig. 4E) known to cause cognitive deficits through enhancing hippocampal inflammation (22), and
of its downstream metabolite urea-1-carboxylate (Suppl. Fig. 4F). LPS-treated mice also had elevated
hippocampal levels of L-phenylalanine (Suppl. Fig. 4G), whose circulating levels are increased in elderly
people with chronic low grade inflammation (23) and prostaglandin-H2-ethanolamide (PGH2-EA) (Suppl.
Fig. 4H), a precursor of prostaglandin E2 (PGE2), which plays a major role in acute inflammation and
transition to chronic inflammation (24), and is a key mediator of LPS-induced sickness (25).
Metabolites sex-dependently affected by LPS
Forty-six metabolites showed sex-dependent effects of LPS, of which twenty-one were selectively
altered in males, twenty were selectively altered in females, and five showed opposite effects in the two
sexes (Table 1). These changes particularly affected two metabolic pathways: pyruvate (Fig. 6) and
methylglyoxal (Fig. 8). Changes in other metabolites known to be associated with immunomodulation are
reported below and illustrated Suppl. Fig. 4.
Metabolic effects of LPS in males
Levels of methylimidazoleacetic acid (Sex X Treatment: F(1,34)=13.22, p=0.0009, Suppl. Fig. 4J), a
metabolite of the pro-inflammatory mediator histamine (26) were increased by LPS in APP/PS1 males.
Other metabolic changes found in LPS-treated males include increased levels of
norepinephrinesulfate (Sex X Treatment: F(1,34)=6.64, p=0.01, Suppl. Fig. 3O), a metabolite of the anti-
inflammatory neurotransmitter norepinephrine (12), choline (Sex X Treatment: F(1,34)=19.89, p<0.0001,
Suppl. Fig. 4K), a precursor of acetylcholine and agonist of α7 nicotinic receptors expressed in neurons 
and macrophages with established anti-inflammatory effects (27, 28), found to dose-dependently inhibit
LPS-induced TNFa production by macrophages (29), L-rhamnose (Sex X Treatment: F(1,34)=7.25, p=0.01,
Suppl. Fig. 4L), previously shown able to inhibit pro-inflammatory cytokines production (30), and
hypoxantine (Sex X Treatment: F(1,34)=10.06, p=0.003, Suppl. Fig. 4M), whose levels are negatively
correlated with the severity of mucosal inflammation (31).
Metabolic effects of LPS in females
6-Phospho-D-gluconate (Suppl. Fig. 4N), an intermediate of the pentose phosphate pathway
known to trigger pro-inflammatory cytokines secretion in LPS-activated macrophages (32), was less
abundant in LPS-treated females
Pro-inflammatory metabolic changes found in LPS-treated females include reduced levels of N2-
Succinyl-L-ornithine (Sex X Treatment: F(1,34)=6.25, p=0.02, Suppl. Fig. 4N), a degradation product of the
anti-inflammatory amino acid arginine (33), and, in WT LPS-treated females, and homoarginine (Suppl.
Fig. 3K), known to be negatively associated with pro-inflammatory changes (14).
Metabolites showing opposite pattern in LPS-treated males and females
Two of the five metabolites that showed opposite effects of LPS in males and females, S-Adenosy-
L-homocysteine Fig. 4E) and N-Succinyl-L-glutamate 5-semialdehyde (Suppl. Fig. 3D), have been reported
to be associated with increased inflammation. They both were found more abundant in male hippocampi
but less abundant in female hippocampi 4 hours after LPS administration.
Suppl. Table 3. Physiological role of metabolites from known metabolic pathways differently expressed between PBS-treated WT and
APP/PS1 mice, PBS-treated males and females and in response to LPS.
Putative metabolite MetabolicPathway Physiological role in the brain
Implication in sex differences
in brain function
Implication in Alzheimer’s
disease (AD) Implication in immune status
Amino acid metabolism
(3R)-beta-Leucine
Valine, leucine and
isoleucine
degradation
Degradation product of L-Leucine
which is produced by muscle protein
catabolism and serves as a donor for
brain glutamate synthesis by
astrocytes and cerebral protein
synthesis (34).
Not known
Increased serum levels of l-leucine
in AD patients and in the 3xTg
mouse model of AD (35).
L-leucine up-regulates tau
phosphorylation in 3xTg mice (35).
L- leucine reduces inflammation
and increases repair after muscle
injury in rats (4).
Choline
Glycine, serine and
threonine
metabolism
Precursor for the cerebral synthesis
of acetylcholine, a neurotransmitter
essential for cognitive function, and
phospholipid phosphatidylcholine, a
major constituent of biological
membranes in neurons and glial cells
(36, 37).
Higher choline concentrations in
the hippocampus of cognitively
intact elderly females (38).
Loss of cholinergic function in AD is
associated with memory decline
(39).
Dietary intake of choline improves
cognitive function in AD patients
and mouse models (37).
Agonist of α7 nicotinic receptors 
expressed on macrophages,
supresses LPS-induced TNFa
production by macrophages (29).
L-cystathionine
Glycine, serine and
threonine
metabolism
Methionine
metabolism
Intermediate in the transsulfuration
pathway which decreases neurotoxic
homocysteine concentrations (40)
Mediates the conversion of
homocysteine into cysteine (Fig. 5).
Not known
Increased levels in the temporal
cortex of post-mortem AD brains
(41).
Inhibits the expression of the pro-
inflammatory cytokine MCP-1 in
macrophages in vitro (42).
L-methionine Methioninemetabolism
Key role in epigenetic regulation in
the brain through conversion into
homocysteine via S-adenosyl-L-
methionine (43).
No differences in mouse brain
concentrations (44).
Decreased levels in the temporal
cortex of post-mortem AD brains
(41).
Elevated CSF levels in MCI and AD
(45).
Excess dietary methionine induces
cognitive and neurological
hallmarks of AD in mice (46).
Excess dietary methionine induces
astrocyte and microglia activation
in the hippocampus (46).
Induces pro-inflammatory
activation in macrophages in vitro
(47).
L-methionine S-oxide Methioninemetabolism
Toxic oxidation product of
methionine (48). Not known
Increased production triggers Aβ 
aggregation (49).
Inhibition reduces TNFa and IL1β 
secretion in LPS-stimulated
microglia (50).
S-adenosyl-L-
homocysteine
Methionine
metabolism
Biosynthetic precursor of
homocysteine (Fig. 5) which is
neurotoxic and pro-inflammatory in
microglia (51).
Formed by demethylation of S-
adenosyl-L-methionine.
No differences in mouse brain
concentrations (44).
Increased levels in the post-
mortem AD brain are associated
with cognitive dysfunction and
neurological hallmarks of AD (52).
Increase Aβ formation in BV-2 
microglial cells (53).
Induces pro-inflammatory
activation in endothelial cells in
vitro (54).
O-succinyl-L-homoserine Methioninemetabolism
Mediates the conversion of
homocysteine into cystathionine
(Fig. 5).
Not known Not known Not known
S-adenosyl-L-
methionine
Methionine
metabolism
Arginine and
proline metabolism
Main donor of methyl groups for
DNA methylation in the brain (43).
Dietary supplementation improves
cognitive abilities in mice (55).
No differences in mouse brain
concentrations (44).
Decreased levels in the post-
mortem AD brain (56) and CSF of
AD patients (57).
Inhibits TNFa production and
enhances IL-6 and IL-10 secretion
in LPS-stimulated human
macrophages and/or murine
monocytes (58, 59).
5'-methylthioadenosine
Methionine
metabolism
Arginine and
proline metabolism
Neuro-protective and anti-
inflammatory derivative of
methionine.
Not known Increased CSF levels in MCIimpaired patients (60).
Reduces brain damage; inhibits
INFg and TNFa production and
enhances IL-10 production in
animal models of
neuroinflammation (61).
N-carbamoylsarcosine Arginine andproline metabolism Not known Not known Not known Not known
N-succinyl-L-glutamate
5-semialdehyde
Arginine and
proline metabolism Not known Not known Not known
Elevated in plasma from lung
cancer patients harbouring a
genetic mutation (7) which
increases their susceptibility to
inflammation (8).
Urea-1-carboxylate Arginine andproline metabolism Not known Not known Not known Not known
Homoarginine Arginine andproline metabolism
Precursor of the free radical nitric
oxide.
Unclear role in healthy brain function
(62).
Not known Not known
Reduced plasma levels associated
with increased C-reactive protein
levels in chronic kidney disease
patients (14).
L-aspartate
Arginine and
proline metabolism
Lysine biosynthesis
Excitatory amino acid and selective
glutamatergic NMDA receptor
agonist (63).
Not known Not known No known
N6-(L-1,3-
Dicarboxypropyl)-L-
lysine
Lysine biosynthesis Not known Not known Not known Not known
N2-acetyl-L-
aminoadipate Lysine biosynthesis Not known Not known Not known Not known
L-2-aminoadipate Lysine degradation
Intermediate in lysine degradation.
Antagonises excitatory NMDA
receptors and reduces kynurenine
levels in the hippocampus (64).
Not known Increased plasma levels in MCI andAD patients (65).
Produced by peritoneal cells in
response to acute inflammation
(66).
Inhibits kynurenine production by
astrocytes (64).
L-pipecolate
Lysine degradation
Alkaloid
biosynthesis I
Major degradation product of lysine
in the murine brain (67). Not known
Reduced CSF levels in MCI, but not
AD, patients (60).
Urine levels are positively
associated with low grade
inflammation in healthy individuals
(10).
(Z)-4-
hydroxyphenylacetaldeh
yde-oxime
Tyrosine
metabolism Not known Not known Not known
Increased gut levels in
inflammatory bowel disease (13).
[FA
hydroxy,oxo(7:0/2:0)]
Tyrosine
metabolism Not known Not known Not known Not known
4-hydroxy-2-oxo-
Heptanedioic acid
L-phenylalanine
Phenylalanine,
tyrosine and
tryptophan
biosynthesis
Dietary precursor of catecholamines.
Accumulation in the brain due to
impaired degradation causes brain
damage and mental retardation
(68).
Not known
Increased circulating levels
correlate with inflammation in a
subgroup of AD patients (69).
Increased circulating levels in
elderly people with chronic low
grade inflammation (23).
L-tryptophan
Phenylalanine,
tyrosine and
tryptophan
biosynthesis
Tryptophan
metabolism
Dietary precursor of serotonin and
vitamin B3 (nicotinic acid).
Improves mood and cognition by
enhancing serotoninergic
neurotransmission (70) and
nicotinamide pathway (71)
Women are more susceptible to
episodic memory impairment
caused by acute tryptophan
depletion (72).
Lower plasma tryptophan levels in
females associated with reduced
serotonin synthesis rate
throughout the brain (73).
Reduced CSF levels in MCI, but not
AD, patients (60).
Reduced serotoninergic
neurotransmission associated with
the development of cognitive
symptoms in AD (74).
Upregulation of kynurenine
pathway associated with
neurological hallmarks of AD (75).
Increases inflammation via
stimulation of the kynurenine
pathway (76).
Serotoninergic neurotransmission
thought to protect against
neuroinflammation (77).
5-hydroxyindoleacetate Tryptophanmetabolism
End metabolite of the serotonin
pathway of tryptophan metabolism
(Fig. 6).
See L-tryptophan Elevated CSF levels in MCI and AD(45). See L-tryptophan
Pantothenate
beta-Alanine
metabolism
Pantothenate and
CoA biosynthesis
Vitamin B5. Substrate for the
biosynthesis of coenzyme A which
contributes to the structure and
function of brain cells via its role in
the synthesis and oxidation of fatty
acids (71).
Not known
Dietary intake positively associated
with cerebral Aβ burden in MCI 
patients (78).
Dietary intake lower systemic
inflammation (C-reactive protein
levels) in healthy adults over 40
(11).
D-alanyl-D-alanine
D-Alanine
metabolism
Peptidoglycan
biosynthesis
Not known Not known Not known Anti-inflammatory antibiotic-binding protein (5).
Glutathione disulphide
(GSSG)
Glutamate
metabolism
Glutathione
metabolism
Toxic oxidation product of the anti-
oxidant glutathione produced and
exported by astrocytes in the brain
(79).
No sex differences in brain tissue
content with aging in mice despite
the most pronounced decline in
glutathione concentrations seen in
males (80).
Higher activity of glutathione
reductase activity, which catalyses
the reduction of GSSG disulphide in
glutathione, in the temporal cortex
of AD patients (81), but unaltered
GSSG contents (82).
Increased circulating levels during
acute systemic inflammation in the
rats (83).
Methylimidazoleacetic
acid
Histidine
metabolism
Main metabolite of histamine, a
neuromodulator, also involved in
cognition, wakefulness and anxiety
and motivated behaviours (84, 85).
Not known Degeneration of histaminergicnerve fibres in AD (86).
Histamine is produced by immune
cells in the brain, induces pro-
inflammatory microglial activation
but inhibits LPS-induced microglial
activation (87).
N(pi)-methyl-L-histidine Histidinemetabolism
Derivative of histidine, a precursor of
brain histamine (85). Not known Not known
Serum histidine levels are
negatively associated with systemic
inflammation (C-reactive protein
levels) in obese women (6).
Hypotaurine Taurine and Intermediate in the synthesis of Not known Not known Suppresses inflammatory and
hypotaurine
metabolism
taurine from the methionine
derivative cysteine (Fig. 5) in
neurons, astrocytes and microglia
(88, 89).
neuropathic pain (90).
Carbohydrate
metabolism
Succinate
Citrate cycle (TCA
cycle)
Glyoxylate and
dicarboxylate
metabolism
Support brain energy metabolism by
promoting ATP generation in
mitochondria (91).
Ameliorates metabolic deficits of
glial cells with mitochondrial
dysfunction (92).
Not known
Reduced whole brain content from
9 months of age in an APP/PS1
mouse model (93).
Pro-inflammatory mediator in
macrophages mediating LPS-
induced IL-1β production (20, 94). 
Isocitrate
Citrate cycle (TCA
cycle)
Glyoxylate and
dicarboxylate
metabolism
Not known Not known
Increased CSF levels in a
transgenic rat model of tauopathy
(95).
Anti-inflammatory in rat model of
anaemia of inflammation (15).
Microglial deficiency in isocitrate
dehydrogenase, the enzyme that
catalyses oxidative decarboxylation
of isocitrate, suppresses LP-induced
pro-inflammatory cytokine
production (TNFa, IL-6, IL-1β) 
(96).
(S)-malate
Citrate cycle (TCA
cycle)
Pyruvate
metabolism
Glyoxylate and
dicarboxylate
metabolism
Metabolite of the KREBS cycle which
promotes mitochondrial ATP
generation and can be recycled into
pyruvate (97).
Not known Not known
Produced by pro-inflammatory
activation of macrophages (98).
(D)-lactate Pyruvatemetabolism
Produced by methylglyoxal
metabolism. Excess levels can cause
encephalopathy (99).
Sex differences in D-lactate
metabolism may contribute to
reduced association between
microbiota and neurological
symptoms in females (100).
Methylglyoxal can cause Aβ 
aggregation (101) and its
neurotoxicity is associated with AD
(102).
Methylglyoxal is pro-inflammatory
and activates glial cells in the brain
(103).
(D)-S-lactoylglutath
ione
Pyruvate
metabolism
Intermediate in the formation of D-
lactate from methylglyoxal. Not known Not known Not known
Phosphoenolpyruvate
Citrate cycle (TCA
cycle)
Pyruvate
metabolism
Glycolysis /
Gluconeogenesis
Intermediate in glycolysis and
gluconeogenesis.
Not known Not known
Systemic LPS increases brain levels
of phosphoenolpyruvate
carboxykinase (104), which
catalyses the conversion of
oxaloacetate to
phosphoenolpyruvate in
gluconeogenesis and has anti-
inflammatory effects on LPS-
induced circulating pro-
inflammatory cytokines levels
(104) and macrophages phenotype
(105).
Pyruvate
Citrate cycle (TCA
cycle)
Glycolysis /
Gluconeogenesis
Intermediate metabolite of glucose
with potent antioxidant and anti-
inflammatory properties (106).
Sex differences in pyruvate
metabolism associated with
reduced oxidative stress and
damage in females (107, 108).
Improves cognitive performance in
mouse models of AD without
affecting tau or Aβ pathology (109, 
110).
Ethyl derivatives of pyruvate
alleviate pro-inflammatory changes
in the brain (111, 112).
D-glyceraldehyde 3-
phosphate
Glycolysis /
Gluconeogenesis
Intermediate in glycolysis and
gluconeogenesis. Not known Not known Not known
3-phospho-D-glycerate
Glycolysis
/Gluconeogenesis
Glyoxylate and
dicarboxylate
metabolism
Conversion of 3-phospho-D-
glycerate to
phosphohydroxypyruvate by the
enzyme 3-phosphoglycerate
dehydrogenase (3PGDH) is the first
step in serine production.
Deficiency in 3PGDH causes brain
atrophy, seizures and psychomotor
retardation (113).
Not known Not known
3PGDH is an astrocytic enzyme that
catalases the production of serine
by neurons and glia (114) and is
anti-inflammatory in fibroblasts
(115).
2-phosphoglycolate
Glyoxolate and
dicatboxylate
metabolism
Possible indicator of damage and
repair of DNA ends (116). Not known
Decreased expression and activity
in AD brain of phosphoglucomutase
1 (PGM1) the glycolytic enzyme
that catalyses the conversion of 3-
phosphoglycerate to 2-
phosphoglycerate (117).
Not known
3-oxalomalate
Glyoxolate and
dicatboxylate
metabolism
Not known Not known Not known Antioxidant in LPS-activatedmacrophages (118).
L-rhamnose
Fructose and
mannose
metabolism
Not known Not known Not known Inhibits pro-inflammatory cytokinesproduction in macrophages (119).
D-sorbitol
Fructose and
mannose
metabolism
Intermediate in the production of
fructose from glucose in the brain
(120).
Not known Elevated levels in the post-mortemAD brain (121).
Anti-inflammatory properties in
resident cells from articular
cartilage (122).
6-phospho-D-gluconate Pentose phosphatepathway
Regulatory control of brain
metabolism (123). Not known
Increased activity of the pentose
phosphate pathway associated with
increased pro-oxidant activity in
the post mortem AD brain (124)
Triggers pro-inflammatory
cytokines secretion in LPS-
activated macrophages (32).
Propanoyl phosphate
Propanoate
metabolism
C5-Branched
dibasic acid
metabolism
Not known Not known Not known Not known
Itaconate
C5-Branched
dibasic acid
metabolism
Citrate cycle (TCA
cycle)
Endogenous antibiotic in the brain
(125). Not known Not known
Anti-inflammatory metabolite found
in macrophages (16) and produced
by microglia (125).
Methyloxaloacetate
C5-Branched
dibasic acid
metabolism
Not known Not known Not known Not known
Nucleotide metabolism
Hypoxanthine Purine metabolism
Endogenous ligand of
benzodiazepine-binding sites in the
brain (126).
Not known
Increased brain concentration in a
transgenic rat model of tauopathy
(95).
Elevated CSF levels in MCI patients
(45).
Hypoxanthine is anti-inflammatory
and depleted in LPS-stimulated
macrophages (127).
Urate Purine metabolism Neuroprotective and antioxidant atphysiological levels (128).
Reduced brain tissue contents in
women (129).
Increased CSF contents in AD
(130).
Trends towards reduced levels in
the post-mortem AD brain (129).
High uric acid diet causes cognitive
deficits by inducing hippocampal
neuroinflammation (22).
Suppresses LPS-induced pro-
inflammatory microglial activation
in vitro (131).
N6-(1,2-
Dicarboxyethyl)-AMP Purine metabolism Not known Not known Not known Not known
Orotate Pyrimidinemetabolism Not known Not known Not known Not known
Thymidine Pyrimidinemetabolism Not known Not known Not known Not known
Thymine Pyrimidinemetabolism Not known Not known Not known Not known
5,6-dihydrouracil
Pyrimidine
metabolism
Beta-Alanine
metabolism
Pantothenate and
CoA biosynthesis
Not known Not known Not known Not known
Lipid metabolism and
Fatty acyls
Octadecanoic acid
(18:0 stearic acid)
Fatty acids
biosynthesis
Biosynthesis of
unsaturated fatty
acids
Needed for the synthesis of
membranes of neurons and
astrocytes during brain development
(132).
No sex differences in mouse brain
content with normal diet (133).
Induces tau phosphorylation in
cultured neurons and astrocytes
(134).
Triggers secretion of Aβ peptide 
(135).
Reduced levels in the post-mortem
AD brain (136).
Accumulates primarily in astrocytes
(137) where it triggers the release
of TNFα and IL-6 (138). 
Hexadecanoic acid
(16:0 palmitic acid)
Biosynthesis of
unsaturated fatty
acids
Dietary administration, which enters
the brain, improves cognitive and
motor function (139).
No sex differences in mouse brain
content with normal diet (133).
Induces tau phosphorylation and
amyloid processing in cultured
neurons and astrocytes (134, 135,
140).
Increased levels in the post-
mortem AD brain (136).
 Triggers astrocytic release of TNFα 
and IL-6 in vitro (138).
Impairs the protective migratory
and phagocytic activities of
microglia in both males and
females (141).
Icosatrienoic acid
20:3
Biosynthesis of
unsaturated fatty
acids
Increased brain levels associated
with reduced brain growth in
developing rats fed with an essential
fatty acid deficient diet (142).
Intermediate in the synthesis of
Arachidonic acid.
Not known Not known Not known
[FA (20:4)]
5Z,8Z,11Z,14Z-
eicosatetraenoic acid
(20:4 Arachidonic acid)
Fatty Acids and
Conjugates
Contributes in brain growth and
function in combination with other
fatty acids (143).
No sex differences in mouse brain
content with normal diet (133).
Triggers secretion of Aβ peptide 
(135).
Reduced levels in the post-mortem
AD brain (136, 144).
Precursor of potent pro-
inflammatory eicosanoids (e.g.
prostaglandins) in astrocytes
(145).
Does not trigger pro-inflammatory
cytokine release in astrocytes
(138).
PGH2-EA Eicosanoids
Metabolite of the endocannabinoid
anandamide known to modulate the
brain reward system (146)
Not known Increases the neurotoxicity of Aβ peptide (147).
Precursor of prostaglandin E2 which
mediates LPS-induced sickness
(148).
Formyl 3-hydroxy-
butanoate Fatty esters Not known Not known Not known Not known
sn-glycerol 3-phosphate
Glycerolipid
metabolism
Glycerophospholipi
d metabolism
Intermediate in the glycolysis
metabolic pathway.
Increased biosynthesis in the
hippocampus during long-term
potentiation (149).
Not known Not known Not known
sn-glycero-3-
Phosphoethanolamine
Glycerophospholipi
d metabolism
Ether lipid
metabolism
Not known. Not known Not known Not known
Energy Metabolism
ATP
Oxidative
phosphorylation
Purine metabolism
Main cellular source of energy in the
brain, which can improve cognitive
function (150).
Greater ATP production in female
mitochondria in the rodent brain
(107)
Decreased brain contents in a
transgenic rat model of tauopathy
(95) and mouse model of
amyloidosis (151).
Pro-inflammatory signalling
molecule in the brain via increased
synthesis of prostaglandin E2 (19).
Produced by microglia and
astrocytes, leading to microglial
activation and chemotactic factor
for microglia towards tissue injury
(152, 153)
D-fructose 1,6-
bisphosphate Carbon fixation
Neuroprotective high energy
glycolytic intermediate (154). Not known Not known
Anti-inflammatory in pain models
(155)
D-sedoheptulose 1,7-
bisphosphate Carbon fixation Not known Not known Not known Not known
Metabolism of Cofactors
and Vitamins
Iminoglycine Thiaminemetabolism Not known Not known Not known Not known
N1-methyl-2-pyridone-
5-carboxamide
Nicotinate and
nicotinamide
metabolism
Toxic end metabolite of the
tryptophan-nicotinamide pathway
(156)
Not known Not known
Elevated circulating levels
associated with systemic
inflammation (157).
Peptides
Gamma
glutamylglutamic acid Peptide Not known Not known Not known Not known
L-beta-aspartyl-L-
glutamicacid Peptide Not known Not known Not known
Belongs to the family of N-acyl-
alpha amino acids and derivatives
which are known for their anti-
inflammatory action (1)
Asp-Ser-His Basic peptide Not known Not known Not known Not known
Asn-Met-Met-Asn Hydrophobicpeptide Not known Not known Not known Not known
Asp-Phe-Thr-Thr Hydrophobicpeptide Not known Not known Not known Not known
Asn-Asn-Asn Polar peptide Not known Not known Not known Not known
Biosynthesis of Polyketides and nonribosomal Peptides
Narbomycin
Biosynthesis of 12-
, 14- and 16-
membered
macrolides
Not known Not known Not known Not known
13-dihydrocarminomycin
Biosynthesis of
type II polyketide
products
Not known Not known Not known Not known
Biosynthesis of Secondary metabolites
Dihydroclavaminic acid
C8H12N2O4
Clavulanic acid
biosynthesis Not known Not known Not known Not known
Not known
γ-aminobutyramide 
C4H10N2O
Not known Not known Not known Not known Not known
1-deoxy-D-altro-
heptulose 7-phosphate Not known Not known Not known Not known Not known
1-methyladenosine Not known
Increased urinary levels in patients
with mild-to-moderate Alzheimer's
disease (3).
Immunosuppressive on
macrophage function (2).
3, 5-
tetradecadiencarnitine Not known Not known Not known Not known Not known
3-methylphosphoenol-
pyruvate Not known Not known Not known Not known Not known
6-methyltetrahydropterin Not known Not known Not known Not known Not known
Athamantin Not known Not known Not known Not known Not known
Camptothecin Not known Not known Not known Not known Not known
Dimethyl citraconate Not known Not known Not known Not known Not known
DL-2-sulfoctanoicacid Not known Not known Not known Not known Not known
Elaidiccarnitine Not known Not known Not known Not known Not known
Glutarylcarnitine Not known Not known Not known Not known Not known
Glycerophosphoglycerol Not known Not known Not known Not known Not known
Linoelaidylcarnitine Not known Not known Not known Not known Not known
N-acetyl-(L)-arginine Not known Not known Not known Not known Not known
NG,NG-dimethyl-L-
arginine Not known Not known Not known Not known Not known
Nocardicin C Not known Not known Not known Not known Not known
Nonulose 9-phosphate Not known Not known Not known Not known Not known
Norepinephrinesulfate Not known Not known Not known Not known Not known
Orotidine Not known Not known Not known Not known Not known
Tetradecanoylcarnitine Not known Not known Not known Not known Not known
GDP-3,6-dideoxy-D-
galactose Not known Not known Not known Not known Not known
N-hydroxyvaline Linamarinbiosynthesis Not known Not known Not known Not known
References
1. Burstein SH. N-Acyl Amino Acids (Elmiric Acids): Endogenous Signaling Molecules with
Therapeutic Potential. Mol Pharmacol. 2018;93(3):228-38.
2. Itoh K, Majima T, Edo K, Mizugaki M, Ishida N. Suppressive effect of 1-methyladenosine on the
generation of chemiluminescence by mouse peritoneal macrophages stimulated with opsonized zymosan.
Tohoku J Exp Med. 1989;157(3):205-14.
3. Lee SH, Kim I, Chung BC. Increased urinary level of oxidized nucleosides in patients with mild-to-
moderate Alzheimer's disease. Clin Biochem. 2007;40(13-14):936-8.
4. Kato H, Miura K, Nakano S, Suzuki K, Bannai M, Inoue Y. Leucine-enriched essential amino acids
attenuate inflammation in rat muscle and enhance muscle repair after eccentric contraction. Amino
Acids. 2016;48(9):2145-55.
5. van der Aart LT, Lemmens N, van Wamel WJ, van Wezel GP. Substrate Inhibition of VanA by d-
Alanine Reduces Vancomycin Resistance in a VanX-Dependent Manner. Antimicrob Agents Chemother.
2016;60(8):4930-9.
6. Niu YC, Feng RN, Hou Y, Li K, Kang Z, Wang J, et al. Histidine and arginine are associated with
inflammation and oxidative stress in obese women. Br J Nutr. 2012;108(1):57-61.
7. Pamungkas AD, Medriano CA, Sim E, Lee S, Park YH. A pilot study identifying a potential plasma
biomarker for determining EGFR mutations in exons 19 or 21 in lung cancer patients. Mol Med Rep.
2017;15(6):4155-61.
8. Jacobs JM, Traeger L, Eusebio J, Simon NM, Sequist LV, Greer JA, et al. Depression, inflammation,
and epidermal growth factor receptor (EGFR) status in metastatic non-small cell lung cancer: A pilot
study. J Psychosom Res. 2017;99:28-33.
9. Han H, Yin J, Wang B, Huang XG, Yao JM, Zheng J, et al. Effects of dietary lysine restriction on
inflammatory responses in piglets. Sci Rep-Uk. 2018;8.
10. Pietzner M, Kaul A, Henning AK, Kastenmuller G, Artati A, Lerch MM, et al. Comprehensive
metabolic profiling of chronic low-grade inflammation among generally healthy individuals. BMC Med.
2017;15(1):210.
11. Jung S, Kim MK, Choi BY. The long-term relationship between dietary pantothenic acid (vitamin
B-5) intake and C-reactive protein concentration in adults aged 40 years and older. Nutr Metab
Cardiovas. 2017;27(9):806-16.
12. Pongratz G, Straub RH. The sympathetic nervous response in inflammation. Arthritis Res Ther.
2014;16(6):504.
13. Jansson J, Willing B, Lucio M, Fekete A, Dicksved J, Halfvarson J, et al. Metabolomics reveals
metabolic biomarkers of Crohn's disease. PLoS One. 2009;4(7):e6386.
14. Ravani P, Maas R, Malberti F, Pecchini P, Mieth M, Quinn R, et al. Homoarginine and mortality in
pre-dialysis chronic kidney disease (CKD) patients. PLoS One. 2013;8(9):e72694.
15. Richardson CL, Delehanty LL, Bullock GC, Rival CM, Tung KS, Kimpel DL, et al. Isocitrate
ameliorates anemia by suppressing the erythroid iron restriction response. J Clin Invest.
2013;123(8):3614-23.
16. Mills EL, Ryan DG, Prag HA, Dikovskaya D, Menon D, Zaslona Z, et al. Itaconate is an anti-
inflammatory metabolite that activates Nrf2 via alkylation of KEAP1. Nature. 2018;556(7699):113-+.
17. Kuda O, Brezinova M, Rombaldova M, Slavikova B, Posta M, Beier P, et al. Docosahexaenoic Acid-
Derived Fatty Acid Esters of Hydroxy Fatty Acids (FAHFAs) With Anti-inflammatory Properties. Diabetes.
2016;65(9):2580-90.
18. Nofal ZM, Fahmy HH, Zarea ES, El-Eraky W. Synthesis of New Pyrimidine Derivatives with
Evaluation of Their Anti-Inflammatory and Analgesic Activities. Acta Pol Pharm. 2011;68(4):507-17.
19. Fiebich BL, Akter S, Akundi RS. The two-hit hypothesis for neuroinflammation: role of exogenous
ATP in modulating inflammation in the brain. Front Cell Neurosci. 2014;8:260.
20. Mills E, O'Neill LA. Succinate: a metabolic signal in inflammation. Trends Cell Biol.
2014;24(5):313-20.
21. McKay TB, Hjortdal J, Sejersen H, Asara JM, Wu J, Karamichos D. Endocrine and Metabolic
Pathways Linked to Keratoconus: Implications for the Role of Hormones in the Stromal
Microenvironment. Sci Rep. 2016;6:25534.
22. Shao XN, Lu WJ, Gao FB, Li DD, Hu J, Li Y, et al. Uric Acid Induces Cognitive Dysfunction through
Hippocampal Inflammation in Rodents and Humans. J Neurosci. 2016;36(43):10990-1005.
23. Capuron L, Schroecksnadel S, Feart C, Aubert A, Higueret D, Barberger-Gateau P, et al. Chronic
Low-Grade Inflammation in Elderly Persons Is Associated with Altered Tryptophan and Tyrosine
Metabolism: Role in Neuropsychiatric Symptoms. Biol Psychiat. 2011;70(2):175-82.
24. Aoki T, Narumiya S. Prostaglandins and chronic inflammation. Trends Pharmacol Sci.
2012;33(6):304-11.
25. Saper CB, Romanovsky AA, Scammell TE. Neural circuitry engaged by prostaglandins during the
sickness syndrome. Nat Neurosci. 2012;15(8):1088-95.
26. Branco ACCC, Yoshikawa FSY, Pietrobon AJ, Sato MN. Role of Histamine in Modulating the
Immune Response and Inflammation. Mediat Inflamm. 2018.
27. Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, et al. Nicotinic acetylcholine receptor
alpha 7 subunit is an essential regulator of inflammation. Nature. 2003;421(6921):384-8.
28. Rowley TJ, McKinstry A, Greenidge E, Smith W, Flood P. Antinociceptive and anti-inflammatory
effects of choline in a mouse model of postoperative pain. Brit J Anaesth. 2010;105(2):201-7.
29. Parrish WR, Puerta MG, Ochani M, Ochani K, Moskovic D, Lin X, et al. Choline suppresses
inflammatory responses. Shock. 2006;25:45-.
30. Watanabe Y, Tateno H, Nakamura-Tsuruta S, Kominami J, Hirabayashi J, Nakamura O, et al. The
function of rhamnose-binding lectin in innate immunity by restricted binding to Gb3. Dev Comp
Immunol. 2009;33(2):187-97.
31. Lee JS, Wang RX, Alexeev EE, Lanis JM, Battista KD, Glover LE, et al. Hypoxanthine is a
checkpoint stress metabolite in colonic epithelial energy modulation and barrier function. J Biol Chem.
2018;293(16):6039-51.
32. Baardman J, Verberk SGS, Prange KHM, van Weeghel M, van der Velden S, Ryan DG, et al. A
Defective Pentose Phosphate Pathway Reduces Inflammatory Macrophage Responses during
Hypercholesterolemia. Cell Rep. 2018;25(8):2044-52 e5.
33. Wu T, Wang C, Ding L, Shen Y, Cui H, Wang M, et al. Arginine Relieves the Inflammatory
Response and Enhances the Casein Expression in Bovine Mammary Epithelial Cells Induced by
Lipopolysaccharide. Mediators Inflamm. 2016;2016:9618795.
34. Yudkoff M, Daikhin Y, Nissim I, Horyn O, Luhovyy B, Luhovyy B, et al. Brain amino acid
requirements and toxicity: the example of leucine. J Nutr. 2005;135(6 Suppl):1531S-8S.
35. Li HJ, Ye D, Xie W, Hua F, Yang YL, Wu J, et al. Defect of branched-chain amino acid metabolism
promotes the development of Alzheimer's disease by targeting the mTOR signaling. Bioscience Rep.
2018;38.
36. Loffelholz K, Klein J, Koppen A. Choline, a Precursor of Acetylcholine and Phospholipids in the
Brain. Progress in Brain Research. 1993;98:197-200.
37. Blusztajn JK, Slack BE, Mellott TJ. Neuroprotective Actions of Dietary Choline. Nutrients.
2017;9(8).
38. Chen CS, Kuo YT, Tsai HY, Li CW, Lee CC, Yen CF, et al. Brain Biochemical Correlates of the
Plasma Homocysteine Level: A Proton Magnetic Resonance Spectroscopy Study in the Elderly Subjects.
Am J Geriat Psychiat. 2011;19(7):618-26.
39. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a
review of progress. J Neurol Neurosur Ps. 1999;66(2):137-47.
40. Hensley K, Denton TT. Alternative functions of the brain transsulfuration pathway represent an
underappreciated aspect of brain redox biochemistry with significant potential for therapeutic
engagement. Free Radical Bio Med. 2015;78:123-34.
41. Gueli MC, Taibi G. Alzheimer's disease: amino acid levels and brain metabolic status. Neurol Sci.
2013;34(9):1575-9.
42. Zhu MZ, Du JB, Liu AD, Holmberg L, Chen SY, Bu DF, et al. L-cystathionine inhibits oxidized low
density lipoprotein-induced THP-1-derived macrophage inflammatory cytokine monocyte
chemoattractant protein-1 generation via the NF-kappa B pathway. Sci Rep-Uk. 2015;5.
43. McGowan PO, Meaney MJ, Szyf M. Diet and the epigenetic (re)programming of phenotypic
differences in behavior. Brain Res. 2008;1237:12-24.
44. Witham KL, Butcher NJ, Sugamori KS, Brenneman D, Grant DM, Minchin RF. 5-methyl-
tetrahydrofolate and the S-adenosylmethionine cycle in C57BL/6J mouse tissues: gender differences and
effects of arylamine N-acetyltransferase-1 deletion. PLoS One. 2013;8(10):e77923.
45. Kaddurah-Daouk R, Zhu H, Sharma S, Bogdanov M, Rozen SG, Matson W, et al. Alterations in
metabolic pathways and networks in Alzheimer's disease. Transl Psychiat. 2013;3.
46. Tapia-Rojas C, Lindsay CB, Montecinos-Oliva C, Arrazola MS, Retamales RM, Bunout D, et al. Is L-
methionine a trigger factor for Alzheimer's-like neurodegeneration?: Changes in Abeta oligomers, tau
phosphorylation, synaptic proteins, Wnt signaling and behavioral impairment in wild-type mice. Mol
Neurodegener. 2015;10:62.
47. Dos Santos LM, da Silva TM, Azambuja JH, Ramos PT, Oliveira PS, da Silveira EF, et al.
Methionine and methionine sulfoxide treatment induces M1/classical macrophage polarization and
modulates oxidative stress and purinergic signaling parameters. Mol Cell Biochem. 2017;424(1-2):69-
78.
48. Stadtman ER, Van Remmen H, Richardson A, Wehr NB, Levine RL. Methionine oxidation and
aging. Biochim Biophys Acta. 2005;1703(2):135-40.
49. Moskovitz J, Du F, Bowman CF, Yan SS. Methionine sulfoxide reductase A affects beta-amyloid
solubility and mitochondrial function in a mouse model of Alzheimer's disease. Am J Physiol Endocrinol
Metab. 2016;310(6):E388-93.
50. Fan H, Wu PF, Zhang L, Hu ZL, Wang W, Guan XL, et al. Methionine Sulfoxide Reductase A
Negatively Controls Microglia-Mediated Neuroinflammation via Inhibiting ROS/MAPKs/NF-kappa B
Signaling Pathways Through a Catalytic Antioxidant Function. Antioxid Redox Sign. 2015;22(10):832-47.
51. Chen S, Dong ZP, Cheng M, Zhao YQ, Wang MY, Sai N, et al. Homocysteine exaggerates microglia
activation and neuroinflammation through microglia localized STAT3 overactivation following ischemic
stroke. J Neuroinflamm. 2017;14.
52. Kennedy BP, Bottiglieri T, Arning E, Ziegler MG, Hansen LA, Masliah E. Elevated S-
adenosylhomocysteine in Alzheimer brain: influence on methyltransferases and cognitive function. J
Neural Transm (Vienna). 2004;111(4):547-67.
53. Lin HC, Hsieh HM, Chen YH, Hu ML. S-Adenosylhomocysteine increases beta-amyloid formation in
BV-2 microglial cells by increased expressions of beta-amyloid precursor protein and presenilin 1 and by
hypomethylation of these gene promoters. Neurotoxicology. 2009;30(4):622-7.
54. Barroso M, Kao D, Blom HJ, de Almeida IT, Castro R, Loscalzo J, et al. S-adenosylhomocysteine
induces inflammation through NFkB: A possible role for EZH2 in endothelial cell activation. Bba-Mol Basis
Dis. 2016;1862(1):82-92.
55. Montgomery SE, Sepehry AA, Wangsgaard JD, Koenig JE. The Effect of S-Adenosylmethionine on
Cognitive Performance in Mice: An Animal Model Meta-Analysis. Plos One. 2014;9(10).
56. Morrison LD, Smith DD, Kish SJ. Brain S-adenosylmethionine levels are severely decreased in
Alzheimer's disease. J Neurochem. 1996;67(3):1328-31.
57. Linnebank M, Popp J, Smulders Y, Smith D, Semmler A, Farkas M, et al. S-Adenosylmethionine Is
Decreased in the Cerebrospinal Fluid of Patients with Alzheimer's Disease. Neurodegener Dis.
2010;7(6):373-8.
58. Pfalzer AC, Choi SW, Tammen SA, Park LK, Bottiglieri T, Parnell LD, et al. S-adenosylmethionine
mediates inhibition of inflammatory response and changes in DNA methylation in human macrophages.
Physiol Genomics. 2014;46(17):617-23.
59. Song ZY, Chen T, Uriarte S, Hill D, Barve S, McClain C. S-Adenosylmethionine (SAMe) modulates
interleukin-10 and interleukin-6, but not TNF, production by adenosine (A2) receptor. Gastroenterology.
2004;126(4):A684-A.
60. Ibanez C, Simo C, Barupal DK, Fiehn O, Kivipelto M, Cedazo-Minguez A, et al. A new metabolomic
workflow for early detection of Alzheimer's disease. J Chromatogr A. 2013;1302:65-71.
61. Moreno B, Hevia H, Santamaria M, Sepulcre J, Munoz J, Garcia-Trevijano ER, et al.
Methylthioadenosine reverses brain autoimmune disease. Ann Neurol. 2006;60(3):323-34.
62. Bernstein HG, Jager K, Dobrowolny H, Steiner J, Keilhoff G, Bogerts B, et al. Possible sources and
functions of L-homoarginine in the brain: review of the literature and own findings. Amino Acids.
2015;47(9):1729-40.
63. Herring BE, Silm K, Edwards RH, Nicoll RA. Is Aspartate an Excitatory Neurotransmitter? J
Neurosci. 2015;35(28):10168-71.
64. Wu HQ, Ungerstedt U, Schwarcz R. L-Alpha-Aminoadipic Acid as a Regulator of Kynurenic Acid
Production in the Hippocampus - a Microdialysis Study in Freely Moving Rats. Eur J Pharmacol.
1995;281(1):55-61.
65. Wang G, Zhou Y, Huang FJ, Tang HD, Xu XH, Liu JJ, et al. Plasma Metabolite Profiles of
Alzheimer's Disease and Mild Cognitive Impairment. J Proteome Res. 2014;13(5):2649-58.
66. Lin H, Levison BS, Buffa JA, Huang Y, Fu X, Wang Z, et al. Myeloperoxidase-mediated protein
lysine oxidation generates 2-aminoadipic acid and lysine nitrile in vivo. Free Radical Bio Med.
2017;104:20-31.
67. Posset R, Opp S, Struys EA, Volkl A, Mohr H, Hoffmann GF, et al. Understanding cerebral L-lysine
metabolism: the role of L-pipecolate metabolism in Gcdh-deficient mice as a model for glutaric aciduria
type I. J Inherit Metab Dis. 2015;38(2):265-72.
68. Williams RA, Mamotte CD, Burnett JR. Phenylketonuria: an inborn error of phenylalanine
metabolism. Clin Biochem Rev. 2008;29(1):31-41.
69. Wissmann P, Geisler S, Leblhuber F, Fuchs D. Immune activation in patients with Alzheimer's
disease is associated with high serum phenylalanine concentrations. J Neurol Sci. 2013;329(1-2):29-33.
70. Jenkins TA, Nguyen JC, Polglaze KE, Bertrand PP. Influence of Tryptophan and Serotonin on Mood
and Cognition with a Possible Role of the Gut-Brain Axis. Nutrients. 2016;8(1).
71. Kennedy DO. B Vitamins and the Brain: Mechanisms, Dose and Efficacy-A Review. Nutrients.
2016;8(2).
72. Sambeth A, Blokland A, Harmer CJ, Kilkens TO, Nathan PJ, Porter RJ, et al. Sex differences in the
effect of acute tryptophan depletion on declarative episodic memory: a pooled analysis of nine studies.
Neurosci Biobehav Rev. 2007;31(4):516-29.
73. Nishizawa S, Benkelfat C, Young SN, Leyton M, Mzengeza S, DeMontigny C, et al. Differences
between males and females in rates of serotonin synthesis in human brain. P Natl Acad Sci USA.
1997;94(10):5308-13.
74. Smith GS, Barrett FS, Joo JH, Nassery N, Savonenko A, Sodums DJ, et al. Molecular imaging of
serotonin degeneration in mild cognitive impairment. Neurobiol Dis. 2017;105:33-41.
75. Wu W, Nicolazzo JA, Wen L, Chung R, Stankovic R, Bao SSS, et al. Expression of Tryptophan 2,3-
Dioxygenase and Production of Kynurenine Pathway Metabolites in Triple Transgenic Mice and Human
Alzheimer's Disease Brain. Plos One. 2013;8(4).
76. Davis I, Liu AM. What is the tryptophan kynurenine pathway and why is it important to
neurotherapeutics? Expert Rev Neurother. 2015;15(7):719-21.
77. Wu H, Denna TH, Storkersen JN, Gerriets VA. Beyond a neurotransmitter: The role of serotonin in
inflammation and immunity. Pharmacol Res. 2019;140:100-14.
78. Lee JH, Ahn SY, Lee HA, Won KS, Chang HW, Oh JS, et al. Dietary intake of pantothenic acid is
associated with cerebral amyloid burden in patients with cognitive impairment. Food Nutr Res. 2018;62.
79. Dringen R, Hirrlinger J. Glutathione pathways in the brain. Biol Chem. 2003;384(4):505-16.
80. Wang H, Liu HL, Liu RM. Gender difference in glutathione metabolism during aging in mice. Exp
Gerontol. 2003;38(5):507-17.
81. Schuessel K, Leutner S, Cairns NJ, Muller WE, Eckert A. Impact of gender on upregulation of
antioxidant defence mechanisms in Alzheimer's disease brain. J Neural Transm. 2004;111(9):1167-82.
82. Adams JD, Jr., Klaidman LK, Odunze IN, Shen HC, Miller CA. Alzheimer's and Parkinson's disease.
Brain levels of glutathione, glutathione disulfide, and vitamin E. Mol Chem Neuropathol. 1991;14(3):213-
26.
83. Ikegami K, Lalonde C, Young YK, Picard L, Demling R. Comparison of plasma reduced glutathione
and oxidized glutathione with lung and liver tissue oxidant and antioxidant activity during acute
inflammation. Shock. 1994;1(4):307-12.
84. Passani MB, Panula P, Lin JS. Histamine in the brain. Front Syst Neurosci. 2014;8:64.
85. Yoshikawa T, Nakamura T, Shibakusa T, Sugita M, Naganuma F, Iida T, et al. Insufficient intake
of L-histidine reduces brain histamine and causes anxiety-like behaviors in male mice. J Nutr.
2014;144(10):1637-41.
86. Panula P, Rinne J, Kuokkanen K, Eriksson KS, Sallmen T, Kalimo H, et al. Neuronal histamine
deficit in Alzheimer's disease. Neuroscience. 1998;82(4):993-7.
87. Barata-Antunes S, Cristovao AC, Pires J, Rocha SM, Bernardino L. Dual role of histamine on
microglia-induced neurodegeneration. Biochim Biophys Acta Mol Basis Dis. 2017;1863(3):764-9.
88. Vitvitsky V, Garg SK, Banerjee R. Taurine biosynthesis by neurons and astrocytes. J Biol Chem.
2011;286(37):32002-10.
89. Brand A, Leibfritz D, Hamprecht B, Dringen R. Metabolism of cysteine in astroglial cells: synthesis
of hypotaurine and taurine. J Neurochem. 1998;71(2):827-32.
90. Hara K, Nakamura M, Haranishi Y, Terada T, Kataoka K, Sata T. Antinociceptive effect of
intrathecal administration of hypotaurine in rat models of inflammatory and neuropathic pain. Amino
Acids. 2012;43(1):397-404.
91. Stovell MG, Mada MO, Helmy A, Carpenter TA, Thelin EP, Yan JL, et al. The effect of succinate on
brain NADH/NAD(+) redox state and high energy phosphate metabolism in acute traumatic brain injury.
Sci Rep. 2018;8(1):11140.
92. Giorgi-Coll S, Amaral AI, Hutchinson PJA, Kotter MR, Carpenter KLH. Succinate supplementation
improves metabolic performance of mixed glial cell cultures with mitochondrial dysfunction. Sci Rep.
2017;7(1):1003.
93. Forster DM, James MF, Williams SR. Effects of Alzheimer's disease transgenes on neurochemical
expression in the mouse brain determined by 1H MRS in vitro. Nmr Biomed. 2012;25(1):52-8.
94. Tannahill GM, Curtis AM, Adamik J, Palsson-McDermott EM, McGettrick AF, Goel G, et al.
Succinate is an inflammatory signal that induces IL-1 beta through HIF-1 alpha. Nature.
2013;496(7444):238-+.
95. Karlikova R, Micova K, Najdekr L, Gardlo A, Adam T, Majerova P, et al. Metabolic status of CSF
distinguishes rats with tauopathy from controls. Alzheimers Res Ther. 2017;9.
96. Chae U, Kim HS, Kim KM, Lee H, Lee HS, Park JW, et al. IDH2 Deficiency in Microglia Decreases
the Pro-inflammatory Response via the ERK and NF-kappaB Pathways. Inflammation. 2018;41(5):1965-
73.
97. Manjeri GR, Rodenburg RJ, Blanchet L, Roelofs S, Nijtmans LG, Smeitink JA, et al. Increased
mitochondrial ATP production capacity in brain of healthy mice and a mouse model of isolated complex I
deficiency after isoflurane anesthesia. J Inherit Metab Dis. 2016;39(1):59-65.
98. O'Neill LA. A broken krebs cycle in macrophages. Immunity. 2015;42(3):393-4.
99. Bosoi CR, Rose CF. Elevated cerebral lactate: Implications in the pathogenesis of hepatic
encephalopathy. Metab Brain Dis. 2014;29(4):919-25.
100. Wallis A, Butt H, Ball M, Lewis DP, Bruck D. Support for the microgenderome invites enquiry into
sex differences. Gut Microbes. 2017;8(1):46-52.
101. Woltjer RL, Maezawa I, Ou JJ, Montine KS, Montine TJ. Advanced glycation endproduct precursor
alters intracellular amyloid-beta/A beta PP carboxy-terminal fragment aggregation and cytotoxicity. J
Alzheimers Dis. 2003;5(6):467-76.
102. Angeloni C, Zambonin L, Hrelia S. Role of methylglyoxal in Alzheimer's disease. Biomed Res Int.
2014;2014:238485.
103. Allaman I, Belanger M, Magistretti PJ. Methylglyoxal, the dark side of glycolysis. Front Neurosci-
Switz. 2015;9.
104. Sadasivam M, Ramatchandirin B, Balakrishnan S, Selvaraj K, Prahalathan C. The role of
phosphoenolpyruvate carboxykinase in neuronal steroidogenesis under acute inflammation. Gene.
2014;552(2):249-54.
105. Ko CW, Counihan D, Wu J, Hatzoglou M, Puchowicz MA, Croniger CM. Macrophages with a deletion
of the phosphoenolpyruvate carboxykinase 1 (Pck1) gene have a more proinflammatory phenotype.
Journal of Biological Chemistry. 2018;293(9):3399-409.
106. Das UN. Pyruvate is an endogenous anti-inflammatory and anti-oxidant molecule. Med Sci
Monitor. 2006;12(5):Ra79-Ra84.
107. Gaignard P, Savouroux S, Liere P, Pianos A, Therond P, Schumacher M, et al. Effect of Sex
Differences on Brain Mitochondrial Function and Its Suppression by Ovariectomy and in Aged Mice.
Endocrinology. 2015;156(8):2893-904.
108. Wagner AK, Bayir H, Ren DX, Puccio A, Zafonte RD, Kochanek PM. Relationships between
cerebrospinal fluid markers of excitotoxicity, ischemia, and oxidative damage after severe TBI: The
impact of gender, age, and hypothermia. J Neurotraum. 2004;21(2):125-36.
109. Isopi E, Granzotto A, Corona C, Bomba M, Ciavardelli D, Curcio M, et al. Pyruvate prevents the
development of age-dependent cognitive deficits in a mouse model of Alzheimer's disease without
reducing amyloid and tau pathology. Neurobiology of Disease. 2015;81:214-24.
110. Koivisto H, Leinonen H, Puurula M, Hafez HS, Barrera GA, Stridh MH, et al. Chronic Pyruvate
Supplementation Increases Exploratory Activity and Brain Energy Reserves in Young and Middle-Aged
Mice. Front Aging Neurosci. 2016;8:41.
111. Lee HK, Kim ID, Kim SW, Lee H, Park JY, Yoon SH, et al. Anti-inflammatory and anti-excitoxic
effects of diethyl oxopropanamide, an ethyl pyruvate bioisoster, exert robust neuroprotective effects in
the postischemic brain. Sci Rep. 2017;7:42891.
112. Lee HK, Kim SW, Jin Y, Kim ID, Park JY, Yoon SH, et al. Anti-inflammatory effects of OBA-09, a
salicylic acid/pyruvate ester, in the postischemic brain. Brain Res. 2013;1528:68-79.
113. Tabatabaie L, Klomp LWJ, Rubio-Gozalbo ME, Spaapen LJM, Haagen AAM, Dorland L, et al.
Expanding the clinical spectrum of 3-phosphoglycerate dehydrogenase deficiency. J Inherit Metab Dis.
2011;34(1):181-4.
114. Ehmsen JT, Ma TM, Sason H, Rosenberg D, Ogo T, Furuya S, et al. D-Serine in Glia and Neurons
Derives from 3-Phosphoglycerate Dehydrogenase. J Neurosci. 2013;33(30):12464-9.
115. Hamano M, Haraguchi Y, Sayano T, Zyao C, Arimoto Y, Kawano Y, et al. Enhanced vulnerability to
oxidative stress and induction of inflammatory gene expression in 3-phosphoglycerate dehydrogenase-
deficient fibroblasts. Febs Open Bio. 2018;8(6):914-22.
116. Knight J, Hinsdale M, Holmes R. Glycolate and 2-phosphoglycolate content of tissues measured by
ion chromatography coupled to mass spectrometry. Anal Biochem. 2012;421(1):121-4.
117. Newman SF, Sultana R, Perluigi M, Coccia R, Cai J, Pierce WM, et al. An increase in S-
glutathionylated proteins in the Alzheimer's disease inferior parietal lobule, a proteomics approach. J
Neurosci Res. 2007;85(7):1506-14.
118. Irace C, Esposito G, Maffettone C, Rossi A, Festa M, Iuvone T, et al. Oxalomalate affects the
inducible nitric oxide synthase expression and activity. Life Sci. 2007;80(14):1282-91.
119. Watanabe Y, Tateno H, Nakamura-Tsuruta S, Kominami J, Hirabayashi J, Nakamura O, et al. The
function of rhamnose-binding lectin in innate immunity by restricted binding to Gb3. Dev Comp
Immunol. 2009;33(2):187-97.
120. Hwang JJ, Jiang L, Hamza M, Dai F, Belfort-DeAguiar R, Cline G, et al. The human brain produces
fructose from glucose. JCI Insight. 2017;2(4):e90508.
121. Xu JS, Begley P, Church SJ, Patassini S, McHarg S, Kureishy N, et al. Elevation of brain glucose
and polyol-pathway intermediates with accompanying brain-copper deficiency in patients with
Alzheimer's disease: metabolic basis for dementia. Sci Rep-Uk. 2016;6.
122. Mongkhon JM, Thach M, Shi Q, Fernandes JC, Fahmi H, Benderdour M. Sorbitol-modified
hyaluronic acid reduces oxidative stress, apoptosis and mediators of inflammation and catabolism in
human osteoarthritic chondrocytes. Inflamm Res. 2014;63(8):691-701.
123. Kauffman FC, Brown JG, Passonneau JV, Lowry OH. Effects of Changes in Brain Metabolism on
Levels of Pentose Phosphate Pathway Intermediates. Journal of Biological Chemistry.
1969;244(13):3647-+.
124. Palmer AM. The activity of the pentose phosphate pathway is increased in response to oxidative
stress in Alzheimer's disease. J Neural Transm. 1999;106(3-4):317-28.
125. Michelucci A, Cordes T, Ghelfi J, Pailot A, Reiling N, Goldmann O, et al. Immune-responsive gene
1 protein links metabolism to immunity by catalyzing itaconic acid production. P Natl Acad Sci USA.
2013;110(19):7820-5.
126. Asano T, Spector S. Identification of Inosine and Hypoxanthine as Endogenous Ligands for the
Brain Benzodiazepine-Binding Sites. P Natl Acad Sci USA. 1979;76(2):977-81.
127. Rattigan KM, Pountain AW, Regnault C, Achcar F, Vincent IM, Goodyear CS, et al. Metabolomic
profiling of macrophages determines the discrete metabolomic signature and metabolomic interactome
triggered by polarising immune stimuli. Plos One. 2018;13(3).
128. Fang P, Li X, Luo JJ, Wang H, Yang XF. A Double-edged Sword: Uric Acid and Neurological
Disorders. Brain Disord Ther. 2013;2(2):109.
129. McFarland NR, Burdett T, Desjardins CA, Frosch MP, Schwarzschild MA. Postmortem brain levels
of urate and precursors in Parkinson's disease and related disorders. Neurodegener Dis.
2013;12(4):189-98.
130. Tohgi H, Abe T, Takahashi S, Kikuchi T. The urate and xanthine concentrations in the
cerebrospinal fluid in patients with vascular dementia of the Binswanger type, Alzheimer type dementia,
and Parkinson's disease. J Neural Transm Park Dis Dement Sect. 1993;6(2):119-26.
131. Bao LH, Zhang YN, Zhang JN, Gu L, Yang HM, Huang YY, et al. Urate inhibits microglia activation
to protect neurons in an LPS-induced model of Parkinson's disease. J Neuroinflamm. 2018;15.
132. Bourre JM, Gozlandevillierre N, Morand O, Baumann N. Importance of Exogenous Saturated Fatty-
Acids during Brain-Development and Myelination in Mice. Ann Biol Anim Bioch. 1979;19(Nb1):173-80.
133. Rodriguez-Navas C, Morselli E, Clegg DJ. Sexually dimorphic brain fatty acid composition in low
and high fat diet-fed mice. Mol Metab. 2016;5(8):680-9.
134. Patil S, Chan C. Palmitic and stearic fatty acids induce Alzheimer-like hyperphosphorylation of tau
in primary rat cortical neurons. Neurosci Lett. 2005;384(3):288-93.
135. Amtul Z, Uhrig M, Rozmahel RF, Beyreuther K. Structural Insight into the Differential Effects of
Omega-3 and Omega-6 Fatty Acids on the Production of A beta Peptides and Amyloid Plaques. Journal of
Biological Chemistry. 2011;286(8):6100-7.
136. Fraser T, Tayler H, Love S. Fatty Acid Composition of Frontal, Temporal and Parietal Neocortex in
the Normal Human Brain and in Alzheimer's Disease. Neurochem Res. 2010;35(3):503-13.
137. Bourre JM, Gozlan-Devillierre N, Pollet S, Maurin Y, Baumann N. In vivo incorporation of
exogenous stearic acid in synaptosomes: high occurrence of non-esterified fatty acids. Neurosci Lett.
1977;4(6):309-13.
138. Gupta S, Knight AG, Gupta S, Keller JN, Bruce-Keller AJ. Saturated long-chain fatty acids activate
inflammatory signaling in astrocytes. J Neurochem. 2012;120(6):1060-71.
139. Moazedi AA, Hossienzadeh Z, Chinpardaz R. The effects of coadministration palmitic acid and oleic
acid (omega 9) on spatial learning and motor activity in adult male rat. Pak J Biol Sci.
2007;10(20):3650-5.
140. Patil S, Sheng L, Masserang A, Chan C. Palmitic acid-treated astrocytes induce BACE1
upregulation and accumulation of C-terminal fragment of APP in primary cortical neurons. Neurosci Lett.
2006;406(1-2):55-9.
141. Yanguas-Casas N, Crespo-Castrillo A, de Ceballos ML, Chowen JA, Azcoitia I, Arevalo MA, et al.
Sex differences in the phagocytic and migratory activity of microglia and their impairment by palmitic
acid. Glia. 2018;66(3):522-37.
142. Odutuga AA. Long-term deficiency of essential fatty acids in rats and its effect on brain recovery.
Clin Exp Pharmacol Physiol. 1979;6(4):361-6.
143. Harauma A, Yasuda H, Hatanaka E, Nakamura MT, Salem N, Jr., Moriguchi T. The essentiality of
arachidonic acid in addition to docosahexaenoic acid for brain growth and function. Prostaglandins Leukot
Essent Fatty Acids. 2017;116:9-18.
144. Snowden SG, Ebshiana AA, Hye A, An Y, Pletnikova O, O'Brien R, et al. Association between fatty
acid metabolism in the brain and Alzheimer disease neuropathology and cognitive performance: A
nontargeted metabolomic study. Plos Med. 2017;14(3).
145. Hussain G, Schmitt F, Loeffler JP, de Aguilar JLG. Fatting the brain: a brief of recent research.
Frontiers in Cellular Neuroscience. 2013;7.
146. Scherma M, Masia P, Satta V, Fratta W, Fadda P, Tanda G. Brain activity of anandamide: a
rewarding bliss? Acta Pharmacol Sin. 2019;40(3):309-23.
147. Boutaud O, Montine TJ, Chang L, Klein WL, Oates JA. PGH2-derived levuglandin adducts increase
the neurotoxicity of amyloid beta1-42. J Neurochem. 2006;96(4):917-23.
148. Saper CB, Romanovsky AA, Scammell TE. Neural circuitry engaged by prostaglandins during the
sickness syndrome. Nat Neurosci. 2012;15(8):1088-95.
149. Martano G, Murru L, Moretto E, Gerosa L, Garrone G, Krogh V, et al. Biosynthesis of glycerol
phosphate is associated with long-term potentiation in hippocampal neurons. Metabolomics. 2016;12(8).
150. Owen L, Sunram-Lea SI. Metabolic Agents that Enhance ATP can Improve Cognitive Functioning:
A Review of the Evidence for Glucose, Oxygen, Pyruvate, Creatine, and L-Carnitine. Nutrients.
2011;3(8):735-55.
151. Zhang C, Rissman RA, Feng J. Characterization of ATP alternations in an Alzheimer's disease
transgenic mouse model. J Alzheimers Dis. 2015;44(2):375-8.
152. Inoue K. Microglial activation by purines and pyrimidines. Glia. 2002;40(2):156-63.
153. Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S, et al. ATP mediates rapid microglial
response to local brain injury in vivo. Nat Neurosci. 2005;8(6):752-8.
154. Izumi Y, Benz AM, Katsuki H, Matsukawa M, Clifford DB, Zorumski CF. Effects of fructose-1,6-
bisphosphate on morphological and functional neuronal integrity in rat hippocampal slices during energy
deprivation. Neuroscience. 2003;116(2):465-75.
155. Veras FP, Peres RS, Saraiva AL, Pinto LG, Louzada-Junior P, Cunha TM, et al. Fructose 1,6-
bisphosphate, a high-energy intermediate of glycolysis, attenuates experimental arthritis by activating
anti-inflammatory adenosinergic pathway. Sci Rep. 2015;5:15171.
156. Lenglet A, Liabeuf S, Bodeau S, Louvet L, Mary A, Boullier A, et al. N-methyl-2-pyridone-5-
carboxamide (2PY)-Major Metabolite of Nicotinamide: An Update on an Old Uremic Toxin. Toxins.
2016;8(11).
157. Sternak M, Khomich TI, Jakubowski A, Szafarz M, Szczepanski W, Bialas M, et al. Nicotinamide N-
methyltransferase (NNMT) and 1-methylnicotinamide (MNA) in experimental hepatitis induced by
concanavalin A in the mouse. Pharmacol Rep. 2010;62(3):483-93.
Supplementary. Fig. 2. Metabolites affected in APP/PS1 mice in the absence of immune
stimulation. Levels of L-beta-aspartyl-L-glutamic acid, were particularly reduced in female
APP/PS1 mice (A). B) 1-Methyladenosine, was more abundant in the hippocampus of
female APP/PS1 mice compared to their WT female littermates (B). Significant Genotype X
Treatment interactions were also found for N-acetyl-(L)-arginine (F(1,34)=12.07, p=0.001),
whose levels were significantly lower in PBS-treated APP/PS1 females compared to PBS-
treated WT females (C), and for the hydrophobic tetrapeptide Asp-Phe-Thr-Thr (F(1,34)=5.40,
p=0.03), whose levels were significantly increased in PBS-treated APP/PS1 males compared
to their PBS-treated counterparts (D). Data are expressed as Means + SEM. Pairwise
comparisons following 3-way ANOVAs: $, p<0.05; $$, p<0.01 compared to WT PBS-treated
(same sex); ##, p<0.01 compared to PBS-treated males (same genotype); *, p<0.05; **,
p<0.01 compared to PBS-treated mice of same sex and genotype.
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Supplementary Figure 3. Metabolites with sex differences in the hippocampus. Data are expressed as
Means + SEM. Post-hoc tests following 3-way ANOVAs: #, p<0.05, ##, p<0.01 compared to PBS-treated males
(same genotype); **, p<0.01; ***, p<0.0001 compared to PBS-treated mice of same sex and genotype.
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Supplementary Figure 4.
Metabolites responding to
LPS in the hippocampus.
Data are expressed as Means
+ SEM. Post-hoc tests
following 3-way ANOVAs: *,
p<0.05; **, p<0.01; ***,
p<0.0001 compared to PBS-
treated mice of same sex and
genotype.
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Supplementary table 3. Results of the two-way repeated measure ANOVAs on glial measures.
% area stained by
Iba1
Number of
cells/mm2
Microglial soma area % area stained by
GFAP
Whole hippocampus
Genotype F(1,35)=0.96; p=0.33 F(1,35)=0.43; p=0.51 F(1,35)=0.00; p=0.95 F(1,33)=3.81; p=0.059
Sex F(1,35)=0.80; p=0.38 F(1,35)=3.28; p=0.08 F(1,35)=2.16; p=0.15 F(1,33)=1.02; p=0.32
Treatment F(1,35)=2.26; p=0.14 F(1,35)=1.39; p=0.24 F(1,35)=0.20; p=0.66 F(1,33)=0.16; p=0.69
Genotype X Sex F(1,35)=4.14; p=0.049 F(1,35)=3.01; p=0.09 F(1,35)=0.20; p=0.75 F(1,33)=0.87; p=0.36
Genotype X Treatment F(1,35)=0.65; p=0.42 F(1,35)=0.22; p=0.64 F(1,35)=0.10; p=0.70 F(1,33)=0.13; p=0.72
Sex X Treatment F(1,35)=0.71; p=0.40 F(1,35)=0.23; p=0.64 F(1,35)=0.75; p=0.39 F(1,33)=0.66; p=0.42
Genotype X Sex X
Treatment
F(1,35)=0.98; p=0.33 F(1,35)=1.75; p=0.19 F(1,35)=0.42; p=0.52 F(1,33)=0.06; p=0.80
CA1
Genotype F(1,35)=1.08; p=0.31 F(1,35)=0.07; p=0.79 F(1,35)=0.02; p=0.90 F(1,33)=4.13; p=0.0503
Sex F(1,35)=1.45; p=0.24 F(1,35)=3.21; p=0.08 F(1,35)=1.60; p=0.21 F(1,33)=1.03; p=0.32
Treatment F(1,35)=3.30; p=0.08 F(1,35)=0.19; p=0.66 F(1,35)=0.15; p=0.70 F(1,33)=0.16; p=0.69
Genotype X Sex F(1,35)=3.56; p=0.07 F(1,35)=1.95; p=0.17 F(1,35)=0.06; p=0.80 F(1,33)=0.43; p=0.52
Genotype X Treatment F(1,35)=0.51; p=0.48 F(1,35)=0.13; p=0.72 F(1,35)=0.03; p=0.86 F(1,33)=0.03; p=0.85
Sex X Treatment F(1,35)=1.15; p=0.29 F(1,35)=0.50; p=0.48 F(1,35)=0.42; p=0.52 F(1,33)=0.20; p=0.66
Genotype X Sex X
Treatment
F(1,35)=0.89; p=0.35 F(1,35)=1.76; p=0.19 F(1,35)=0.52; p=0.48 F(1,33)=0.68; p=0.42
CA2
Genotype F(1,35)=0.82; p=0.37 F(1,34)=0.45; p=0.51 F(1,34)=0.34; p=0.56 F(1,32)=0.18; p=0.67
Sex F(1,35)=0.73; p=0.40 F(1,34)=0.66; p=0.42 F(1,34)=2.01; p=0.16 F(1,32)=0.13; p=0.72
Treatment F(1,35)=1.29; p=0.26 F(1,34)=1.00; p=0.32 F(1,34)=0.22; p=0.64 F(1,32)=1.93; p=0.17
Genotype X Sex F(1,35)=4.24; p=0.047 F(1,34)=2.26; p=0.14 F(1,34)=0.04; p=0.84 F(1,32)=0.03; p=0.87
Genotype X Treatment F(1,35)=0.02; p=0.90 F(1,34)=0.10; p=0.75 F(1,34)=0.09; p=0.77 F(1,32)=0.00; p=0.99
Sex X Treatment F(1,35)=0.11; p=0.74 F(1,34)=0.61; p=0.44 F(1,34)=0.93; p=0.34 F(1,32)=1.54; p=0.22
Genotype X Sex X
Treatment
F(1,35)=0.29; p=0.59 F(1,34)=0.03; p=0.85 F(1,34)=0.95; p=0.33 F(1,32)=0.13; p=0.71
CA3
Genotype F(1,36)=2.50; p=0.12 F(1,36)=1.79; p=0.19 F(1,36)=0.00; p=0.99 F(1,33)=1.21; p=0.28
Sex F(1,36)=0.97; p=0.33 F(1,36)=1.55; p=0.22 F(1,36)=3.62; p=0.06 F(1,33)=0.41; p=0.53
Treatment F(1,36)=1.77; p=0.19 F(1,36)=3.08; p=0.09 F(1,36)=0.01; p=0.93 F(1,33)=0.24; p=0.63
Genotype X Sex F(1,36)=7.37; p=0.01 F(1,36)=3.04; p=0.09 F(1,36)=0.00; p=0.96 F(1,33)=0.76; p=0.39
Genotype X Treatment F(1,36)=0.56; p=0.46 F(1,36)=0.59; p=0.45 F(1,36)=0.16; p=0.69 F(1,33)=0.09; p=0.76
Sex X Treatment F(1,36)=0.98; p=0.33 F(1,36)=0.03; p=0.85 F(1,36)=0.68; p=0.41 F(1,33)=1.15; p=0.29
Genotype X Sex X
Treatment
F(1,36)=0.47; p=0.49 F(1,36)=0.05; p=0.82 F(1,36)=1.08; p=0.30 F(1,33)=0.01; p=0.93
Dentate Gyrus
Genotype F(1,36)=1.33; p=0.26 F(1,36)=0.17; p=0.68 F(1,36)=0.04; p=0.83 F(1,33)=3.43; p=0.07
Sex F(1,36)=0.82; p=0.37 F(1,36)=3.69; p=0.06 F(1,36)=2.82; p=0.10 F(1,33)=0.15; p=0.70
Treatment F(1,36)=3.15; p=0.08 F(1,36)=0.00; p=0.99 F(1,36)=0.75; p=0.39 F(1,33)=0.09; p=0.77
Genotype X Sex F(1,36)=2.81; p=0.10 F(1,36)=5.02; p=0.03 F(1,36)=0.01; p=0.92 F(1,33)=0.68; p=0.41
Genotype X Treatment F(1,36)=0.14; p=0.71 F(1,36)=0.45; p=0.50 F(1,36)=0.50; p=0.48 F(1,33)=0.94; p=0.34
Sex X Treatment F(1,36)=0.51; p=0.48 F(1,36)=0.11; p=0.74 F(1,36)=0.96; p=0.34 F(1,33)=1.75; p=0.19
Genotype X Sex X
Treatment
F(1,36)=0.83; p=0.36 F(1,36)=1.17; p=0.29 F(1,36)=0.02; p=0.90 F(1,33)=0.10; p=0.76
F) Whole hippocampus
B) CA1 C) CA2
D) CA3 E) Dentate Gyrus
Supplementary Figure 5. Microglial soma size a morphometric marker of microglial activation was
measured using Iba1 immunostaining at 4 hours after the PBS or LPS challenge. Illustration of the
regions of interests used for microglia and astrocytes segmentation, delineated using a custom made
Matlab tool. No differences were found in the whole hippocampus (B), CA1(C), CA2 (D), CA3 (E) or
Dentate Gyrus (F) subfields. The number of microglial clusters was elevated in APP/PS1 mice
(F(1,35)=10.05, p=0.003; G), which displayed relatively few plaques (white arrows) at 4.5 months of
age (H, I). *, p<0.05. Data are expressed as Means + SEM.
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Supplementary Figure 6. The area occupied by astrocytes was quantified using GFAP
immunostaining 4 hours after the PBS or LPS challenge. Representative image of GFAP positive
astrocytes in the whole hippocampus (A), CA1(B), CA2 (C), CA3 (D) or Dentate Gyrus (E) subfields.
No differences were found between any of the experimental conditions in these regions of interests:
whole hippocampus (F), CA1(G), CA2 (H), CA3 (I) or Dentate Gyrus (J). Data are expressed as
Means + SEM.
Highlights:
 Hippocampal metabolic profile of females is more pro-inflammatory and pro-oxidant
 Comparable LPS-induced sickness behaviour in male and female WT and APP/PS1 mice
 Pro- and anti-inflammatory pathways both recruited 4h after systemic LPS
 Predominant anti-inflammatory metabolic response to LPS in female hippocampi
